Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated Jul 8, 2026·v1

Atrial Fibrillation [probe-off]

Atrial fibrillation is a common, progressive arrhythmia managed via the ABC pathway: Anticoagulation (DOACs preferred), Better symptom control (early rhythm control/ablation), and Cardiovascular risk factor modification.

High Evidence574 references·7,652 words·31 min read·v1
CardiologyArrhythmiaStroke PreventionCatheter Ablation

Quick Reference

RxDrug of choiceApixaban (5 mg BID) or other DOACs for stroke prevention; Beta-blockers for rate control.
AltAlternativesWarfarin (if mechanical valve/mitral stenosis); Digoxin (for rate control in HF); Amiodarone or Flecainide (rhythm control).
⊘AvoidNon-dihydropyridine CCBs in HFrEF; Flecainide/Propafenone in structural heart disease or CAD.
DxTest of choice12-lead ECG (diagnostic); Transthoracic Echocardiogram (structural evaluation).
ScKey scoreCHA2DS2-VASc (stroke risk); HAS-BLED (bleeding risk).
→When to referSymptomatic paroxysmal AF for ablation; HFrEF with AF; failure of rate/rhythm medical therapy.
AF is a progressive disease requiring a three-pronged approach: anticoagulation (DOACs preferred), early rhythm control (ablation/AADs), and aggressive risk factor modification.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, characterized by rapid, disorganized atrial electrical activity and an irregularly irregular ventricular response. It is a progressive disease continuum, now classified into four stages from 'At Risk' to 'Permanent', that affects over 10 million adults in the U.S. and significantly increases the risk of ischemic stroke, heart failure, and all-cause mortality. Pathophysiology involves electrical and structural remodeling, often driven by the NLRP3 inflammasome and TGF-beta-1-mediated fibrosis. Management has undergone a paradigm shift toward the 'ABC' pathway: Anticoagulation to prevent stroke, Better symptom control through early rhythm or rate management, and Cardiovascular risk factor optimization. Landmark trials like EAST-AFNET 4 and CASTLE-AF have established that early rhythm control, particularly via catheter ablation, improves long-term outcomes and reduces mortality in patients with heart failure.

Overview and Recommendations

Background

  • •Atrial fibrillation (AF) is a progressive supraventricular tachyarrhythmia defined by the absence of discrete P waves and an irregularly irregular ventricular rhythm, currently affecting approximately 10.55 million U.S. adults with prevalence projected to double by 2050.
  • •The 2023 ACC/AHA/ACCP/HRS guidelines introduced a four-stage classification system (Stage 1: At Risk; Stage 2: Pre-AF; Stage 3: Clinical AF; Stage 4: Permanent AF) to emphasize that AF is a disease continuum requiring early intervention before irreversible structural remodeling occurs.
  • •Clinical variants are categorized by duration: paroxysmal (terminates within 7 days), persistent (lasts >7 days), and long-standing persistent (>12 months), with the 'atrial fibrillation begets atrial fibrillation' phenomenon driven by electrical and structural remodeling.
  • •Major risk factors include advanced age, (present in >70% of cases), obesity (every 5 kg/m2 increase in BMI significantly raises risk), and sleep apnea, which promote atrial fibrosis and electrical instability.
  • •Prognostic stakes are high, as AF increases stroke risk 5-fold and is associated with a 2-fold increase in mortality when it develops after a diagnosis.

Evaluation

  • •Suspect AF in any patient presenting with palpitations, exertional dyspnea, unexplained fatigue, or an irregularly irregular pulse on physical examination.
  • •Confirm the diagnosis with a standard 12-lead ECG or a single-lead ECG tracing showing an irregular rhythm without P waves lasting at least 30 seconds.
  • •Examine for the hallmark 'pulse deficit' (difference between apical and radial rates) and the absence of 'a' waves in the jugular venous pulse.
  • •Order a transthoracic echocardiogram (TTE) to assess left ventricular ejection fraction (LVEF), valvular pathology, and left atrial volume index (LAVI); a LAVI > 40 mL/m² is a strong predictor of mortality.
  • •Assess for reversible triggers by ordering thyroid-stimulating hormone (TSH) to screen for hyperthyroidism and a complete blood count (CBC) to evaluate for anemia or infection.
  • •Evaluate renal function (eGFR) and hepatic function to guide the selection and dosing of anticoagulants and antiarrhythmic drugs.
  • •Utilize extended rhythm monitoring (e.g., 14-day patch or insertable cardiac monitor) in patients with cryptogenic stroke or paroxysmal symptoms and a non-diagnostic resting ECG.
  • •Calculate the score for all patients to determine thromboembolic risk and the score to identify modifiable bleeding risks.
  • •Screen for obstructive sleep apnea (OSA) in all AF patients, as its prevalence ranges from 21% to 74% and it significantly hinders rhythm control success.

Management

  • •Perform immediate synchronized electrical cardioversion for any patient with hemodynamic instability, such as hypotension, acute pulmonary edema, or active myocardial ischemia.
  • •Initiate stroke prevention using the 'ABC' pathway; for non-valvular AF, (DOACs) are preferred over due to a 51% reduction in hemorrhagic stroke.
  • •Administer 5 mg BID as a first-line DOAC, reducing to 2.5 mg BID if the patient meets two of the following: age ≥80, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
  • •Prescribe 20 mg daily with the largest meal of the day, reducing to 15 mg daily if CrCl is 15-50 mL/min.
  • •Prioritize early rhythm control (within 1 year of diagnosis) using antiarrhythmic drugs or catheter ablation to reduce cardiovascular death and stroke (HR 0.79).
  • •Refer for catheter ablation as first-line therapy for symptomatic paroxysmal AF or in patients with HFrEF, where it has been shown to reduce mortality (NNT = 6).
  • •Utilize (start 1.25-2.5 mg daily) or (start 25-50 mg daily) for rate control, targeting a resting heart rate < 110 bpm.
  • •Consider (62.5-125 mcg daily) for rate control in patients with concomitant heart failure, as it may improve symptoms more effectively than beta-blockers in permanent AF.
  • •Implement aggressive risk factor modification, including a weight loss goal of >10% and alcohol abstinence, which can reduce recurrence risk by half.
  • •Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with LVEF ≤ 40% due to their negative inotropic effects.
  • •Consider left atrial appendage closure (LAAC) for patients with a high stroke risk who have absolute contraindications to long-term anticoagulation.
  • •Monitor patients on with baseline and periodic TSH, liver function tests, and pulmonary function tests due to its extensive side-effect profile.

Board Review — High Yield

  • •Irregularly irregular, The classic pulse and ECG description of AF due to disorganized atrial impulses.
  • •Absent 'a' wave, Found in the jugular venous pulse because there is no coordinated atrial contraction.
  • •Holiday Heart Syndrome, Acute AF triggered by excessive alcohol consumption, often reversible.
  • •Ashman Phenomenon, A long R-R interval followed by a short R-R interval resulting in an aberrantly conducted QRS (usually RBBB).
  • •Lone AF, Historical term for AF in patients <60 years without structural heart disease or risk factors (now discouraged).
  • •CASTLE-AF Trial, Demonstrated that catheter ablation reduces mortality and HF hospitalizations in patients with HFrEF.
  • •EAST-AFNET 4 Trial, Showed that early rhythm control (within 1 year) reduces major cardiovascular events.
  • •Pulsed-Field Ablation, A newer, non-thermal ablation modality that uses electroporation to spare the esophagus and phrenic nerve.
  • •Atrial Functional Mitral Regurgitation, Mitral regurgitation caused by atrial and annular dilation rather than primary leaflet disease.

Deep Dive — Evidence Details

References

  1. [1]

    Ndumele CE, Rodriguez F, Dixon DL et al.. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2026). PMID: 42263157 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Long-term Guideline-Directed Therapy
  2. [2]

    Joglar JA, Chung MK, Armbruster AL et al.. “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2023). PMID: 38033089 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  3. [3]

    Heidenreich PA, Bozkurt B, Aguilar D et al.. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2022). PMID: 35363499 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Special Populations and Prevention
  4. [4]

    Rao SV, O'Donoghue ML, Ruel M et al.. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2025). PMID: 40014670 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  5. [5]

    Ommen SR, Ho CY, Asif IM et al.. “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Circulation (2024). PMID: 38718139 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Special Populations and Prevention
  6. [6]

    Heidenreich PA, Bozkurt B, Aguilar D et al.. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2022). PMID: 35363500 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  7. [7]

    Wigginton JG, Agarwal S, Bartos JA et al.. “Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.” Circulation (2025). PMID: 41122884 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  8. [8]

    Arnett DK, Blumenthal RS, Albert MA et al.. “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Circulation (2019). PMID: 30879339 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  9. [9]

    Heidenreich PA, Bozkurt B, Aguilar D et al.. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2022). PMID: 35379503 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Special Populations and Prevention
  10. [10]

    Rao SV, O'Donoghue ML, Ruel M et al.. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2025). PMID: 40013746 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  11. [11]

    Joglar JA, Chung MK, Armbruster AL et al.. “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2023). PMID: 38043043 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  12. [12]

    Kittleson MM, Ambardekar AV, Cheng RK et al.. “Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.” Journal of the American College of Cardiology (2025). PMID: 41171219 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy, History and Evolution of Treatment
  13. [13]

    Osmancik P, Herman D, Neuzil P et al.. “Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.” Journal of the American College of Cardiology (2020). PMID: 32586585 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
  14. [14]

    Reddy VY, Doshi SK, Kar S et al.. “5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.” Journal of the American College of Cardiology (2017). PMID: 29103847 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  15. [15]

    van Veldhuisen SL, Gorter TM, van Woerden G et al.. “Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.” European heart journal (2022). PMID: 35243488 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Complications, Prognosis and Natural History
  16. [16]

    Willems S, Borof K, Brandes A et al.. “Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial.” European heart journal (2022). PMID: 34447995 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  17. [17]

    Hohnloser SH, Camm J, Cappato R et al.. “Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.” European heart journal (2019). PMID: 30976787 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  18. [18]

    Davidson KW, Barry MJ, Mangione CM et al.. “Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement.” JAMA (2022). PMID: 35076659 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation
  19. [19]

    Yndigegn T, Lindahl B, Mars K et al.. “Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.” The New England journal of medicine (2024). PMID: 38587241 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  20. [20]

    Healey JS, Lopes RD, Granger CB et al.. “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37952132 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  21. [21]

    Ruff CT, Patel SM, Giugliano RP et al.. “Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.” The New England journal of medicine (2025). PMID: 39842011 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification
  22. [22]

    Connolly SJ, Karthikeyan G, Ntsekhe M et al.. “Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.” The New England journal of medicine (2022). PMID: 36036525 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  23. [23]

    Lee SJ, Yu HT, Lee YJ et al.. “Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.” The New England journal of medicine (2025). PMID: 41211917 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Interventional and Device Therapy
  24. [24]

    Sohns C, Fox H, Marrouche NF et al.. “Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37634135 ↗

    L2RCTCited in: Definition, Classification and Nomenclature, Interventional and Device Therapy
  25. [25]

    Lindholt JS, Søgaard R, Rasmussen LM et al.. “Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial.” The New England journal of medicine (2022). PMID: 36027560 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  26. [26]

    Leon MB, Smith CR, Mack MJ et al.. “Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.” The New England journal of medicine (2016). PMID: 27040324 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  27. [27]

    Shoureshi P, Tan AY, Koneru J et al.. “Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38811098 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup
  28. [28]

    Rossi GP. “Primary Aldosteronism: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2019). PMID: 31779795 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Complications
  29. [29]

    Werring DJ, Dehbi HM, Ahmed N et al.. “Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial.” Lancet (London, England) (2024). PMID: 39491870 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  30. [30]

    Svendsen JH, Diederichsen SZ, Højberg S et al.. “Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial.” Lancet (London, England) (2021). PMID: 34469766 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  31. [31]

    Svennberg E, Friberg L, Frykman V et al.. “Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.” Lancet (London, England) (2021). PMID: 34469764 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  32. [32]

    Oraii A, McIntyre WF, Parkash R et al.. “Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.” JAMA cardiology (2024). PMID: 38656292 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Prognosis and Natural History
  33. [33]

    Kahwati LC, Asher GN, Kadro ZO et al.. “Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2022). PMID: 35076660 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  34. [34]

    Jonas DE, Kahwati LC, Yun JDY et al.. “Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2018). PMID: 30088015 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature
  35. [35]

    Attia ZI, Harmon DM, Behr ER et al.. “Application of artificial intelligence to the electrocardiogram.” European heart journal (2021). PMID: 34534279 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  36. [36]

    Kany S, Jurgens SJ, Rämö JT et al.. “Genetic testing in early-onset atrial fibrillation.” European heart journal (2024). PMID: 39028637 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  37. [37]

    Svennberg E, Freedman B, Andrade JG et al.. “Recent-onset atrial fibrillation: challenges and opportunities.” European heart journal (2026). PMID: 40873195 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  38. [38]

    Lu Y, Sun Y, Cai L et al.. “Non-traditional risk factors for atrial fibrillation: epidemiology, mechanisms, and strategies.” European heart journal (2025). PMID: 39716283 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, History and Evolution of Treatment, Special Populations and Prevention
  39. [39]

    Gladstone DJ, Wachter R, Schmalstieg-Bahr K et al.. “Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial.” JAMA cardiology (2021). PMID: 33625468 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  40. [40]

    Pathak RK, Elliott AD, Lau DH et al.. “Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 41160038 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  41. [41]

    Hu X, Jiang W, Wang X et al.. “Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 41060665 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  42. [42]

    Sang C, Liu Q, Lai Y et al.. “Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial.” JAMA (2025). PMID: 39556379 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  43. [43]

    Wijesurendra R, Pessoa-Amorim G, Buck G et al.. “Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial.” JAMA (2025). PMID: 40878848 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  44. [44]

    Marrouche NF, Wazni O, McGann C et al.. “Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial.” JAMA (2022). PMID: 35727277 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy, Prognosis and Natural History
  45. [45]

    Kosiborod MN, Cherney D, Connelly K et al.. “Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics.” JACC. Heart failure (2024). PMID: 38878009 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  46. [46]

    Cohen JB, Schrauben SJ, Zhao L et al.. “Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.” JACC. Heart failure (2020). PMID: 31926856 ↗

    L2RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  47. [47]

    Litwin SE, Komtebedde J, Hu M et al.. “Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction.” JACC. Heart failure (2023). PMID: 36939661 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  48. [48]

    Noseworthy PA, Attia ZI, Behnken EM et al.. “Artificial intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: a prospective non-randomised interventional trial.” Lancet (London, England) (2022). PMID: 36179758 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  49. [49]

    Ndumele CE, Rodriguez F, Dixon DL et al.. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2026). PMID: 42265997 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Special Populations and Prevention
  50. [50]

    Kondo T, Jering KS, Jhund PS et al.. “Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation.” Circulation. Heart failure (2023). PMID: 37350280 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  51. [51]

    Zylla MM, Leiner J, Rahm AK et al.. “Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure and Preserved Ejection Fraction.” Circulation. Heart failure (2022). PMID: 36126143 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
  52. [52]

    MacGowan H, Brown OI, Drozd M et al.. “Comorbidity trajectories before and after the diagnosis of heart failure: A UK Biobank cohort study.” European journal of heart failure (2025). PMID: 39935109 ↗

    L2COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup
  53. [53]

    Grams ME, Coresh J, Matsushita K et al.. “Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.” JAMA (2023). PMID: 37787795 ↗

    L2SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications, Special Populations and Prevention
  54. [54]

    Campbell BCV, Khatri P. “Stroke.” Lancet (London, England) (2020). PMID: 32653056 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  55. [55]

    Lane DA, Andrade JG, Arbelo E et al.. “Atrial fibrillation.” Lancet (London, England) (2026). PMID: 41794418 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  56. [56]

    Maron BJ, Maron MS. “Hypertrophic cardiomyopathy.” Lancet (London, England) (2012). PMID: 22874472 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Special Populations and Prevention
  57. [57]

    Hankey GJ. “Stroke.” Lancet (London, England) (2016). PMID: 27637676 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  58. [58]

    Mueller C, McDonald K, de Boer RA et al.. “Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.” European journal of heart failure (2019). PMID: 31222929 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
  59. [59]

    Nagueh SF. “Non-invasive assessment of left ventricular filling pressure.” European journal of heart failure (2017). PMID: 28990316 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  60. [60]

    Ferrari R, Böhm M, Cleland JG et al.. “Heart failure with preserved ejection fraction: uncertainties and dilemmas.” European journal of heart failure (2015). PMID: 26079097 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment, Prognosis and Natural History
  61. [61]

    Meder B, Coats CJ, Leinwand LA et al.. “EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.” European journal of heart failure (2026). PMID: 41771101 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Special Populations and Prevention
  62. [62]

    Pieske B, Tschöpe C, de Boer RA et al.. “How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).” European heart journal (2019). PMID: 31504452 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  63. [63]

    Du D, Liu S, He S et al.. “Prevalence and clinical characteristics of sleep apnea in hypertrophic cardiomyopathy: A meta-analysis.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 42260027 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature
  64. [64]

    Anand V, Bonow RO, Nishimura RA et al.. “Myocardial Dysfunction in Primary Mitral Regurgitation: A Review.” JAMA cardiology (2026). PMID: 41405892 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  65. [65]

    Ko D, Chung MK, Evans PT et al.. “Atrial Fibrillation: A Review.” JAMA (2025). PMID: 39680399 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  66. [66]

    Milwidsky A, Mathai SV, Topilsky Y et al.. “Medical Therapy for Functional Mitral Regurgitation.” Circulation. Heart failure (2022). PMID: 35862021 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  67. [67]

    Desai MY, Maurizi N, Biagini E et al.. “Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy.” JACC. Heart failure (2025). PMID: 40997544 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
  68. [68]

    Braunwald E. “Heart failure.” JACC. Heart failure (2013). PMID: 24621794 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  69. [69]

    Carlisle MA, Fudim M, DeVore AD et al.. “Heart Failure and Atrial Fibrillation, Like Fire and Fury.” JACC. Heart failure (2019). PMID: 31146871 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  70. [70]

    Zeitler EP, Johnson AE, Cooper LB et al.. “Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction: New Assessment of an Old Problem.” JACC. Heart failure (2024). PMID: 39152985 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy, Complications
  71. [71]

    Reddy YNV, Noseworthy P, Borlaug BA et al.. “Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF.” JACC. Heart failure (2024). PMID: 38839160 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  72. [72]

    Li S, Sun Y, Lai Y et al.. “Heart Failure Medication Withdrawal in Patients With Improved Cardiac Function After Atrial Fibrillation Ablation: The DEFINITION-AF Pilot Randomized Clinical Trial.” JAMA network open (2026). PMID: 42360743 ↗

    L2RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Acute and Initial Management, History and Evolution of Treatment, Complications
  73. [73]

    Roten L, Kueffer T, Badertscher P et al.. “Autonomic effects and ablation success after pulsed field and cryoballoon ablation: a SINGLE SHOT CHAMPION substudy.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 42300255 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, History and Evolution of Treatment
  74. [74]

    Ozaki T, Inoue K, Mishima T et al.. “Impact of Diabetes on the Efficacy of Low-Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS-AF Trial.” Journal of the American Heart Association (2026). PMID: 42294760 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, History and Evolution of Treatment
  75. [75]

    Deng C, Xu Y, Adilijiang A et al.. “Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta-Analysis of Randomized Trials.” Cardiovascular therapeutics (2026). PMID: 42411564 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  76. [76]

    Clapham RE, Speed V, Cox C et al.. “Identifying risk factors for venous thromboembolism in medical inpatients: a systematic review and meta-analysis.” Research and practice in thrombosis and haemostasis (2026). PMID: 42318434 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation, Severity Staging and Risk Stratification, History and Evolution of Treatment
  77. [77]

    Weerts J, Țica O, Aranyo J et al.. “Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC.” European journal of heart failure (2025). PMID: 40763073 ↗

    L1OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Complications
  78. [78]

    Rosano GMC, Moura B, Metra M et al.. “Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.” European journal of heart failure (2021). PMID: 33932268 ↗

    L1OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy
  79. [79]

    Pieske B, Tschöpe C, de Boer RA et al.. “How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).” European journal of heart failure (2020). PMID: 32133741 ↗

    L1OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  80. [80]

    Rämö JT, Kany S, Hou CR et al.. “Cardiovascular Significance and Genetics of Epicardial and Pericardial Adiposity.” JAMA cardiology (2024). PMID: 38477908 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup
  81. [81]

    Karim S, Chahal A, Venkataraman S et al.. “Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy.” JAMA cardiology (2025). PMID: 40900558 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  82. [82]

    Ajufo E, Kany S, Jurgens SJ et al.. “Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers.” JAMA cardiology (2026). PMID: 41205222 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature
  83. [83]

    Akhtar MM, Lorenzini M, Cicerchia M et al.. “Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene.” Circulation. Heart failure (2020). PMID: 32964742 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Prognosis and Natural History
  84. [84]

    Tahir UA, Kolm P, Kwong RY et al.. “Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.” Circulation. Heart failure (2024). PMID: 39498543 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Complications
  85. [85]

    Azzo JD, Dib MJ, Zagkos L et al.. “Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction.” Circulation. Heart failure (2024). PMID: 38299345 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  86. [86]

    Buckley LF, Agha AM, Dorbala P et al.. “MMP-2 Associates With Incident Heart Failure and Atrial Fibrillation: The ARIC Study.” Circulation. Heart failure (2023). PMID: 37753653 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Complications
  87. [87]

    Reddy YNV, Frantz RP, Hassoun PM et al.. “Left Heart Abnormalities in Patients With Lung Disease, OSA, and Chronic Thromboemboli at Risk for or With Known Pulmonary Hypertension.” Circulation. Heart failure (2025). PMID: 40438933 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Complications
  88. [88]

    Carnicelli AP, Hong H, Connolly SJ et al.. “Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.” Circulation (2022). PMID: 34985309 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  89. [89]

    Maron BJ, Desai MY, Nishimura RA et al.. “Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2022). PMID: 35086661 ↗

    L5SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  90. [90]

    Pokorney SD, Chertow GM, Al-Khalidi HR et al.. “Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.” Circulation (2022). PMID: 36335914 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  91. [91]

    Gawałko M, Middeldorp ME, Saljic A et al.. “Diet and risk of atrial fibrillation: a systematic review.” European heart journal (2024). PMID: 39288159 ↗

    L5SR_OBSCited in: Epidemiology and Risk Factors
  92. [92]

    Kim MS, Kim WJ, Khera AV et al.. “Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies.” European heart journal (2021). PMID: 34333589 ↗

    L2SR_OBSCited in: Epidemiology and Risk Factors, Clinical Presentation, Complications
  93. [93]

    Jørgensen TH, Thyregod HGH, Savontaus M et al.. “Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial.” European heart journal (2024). PMID: 38747246 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  94. [94]

    Khan MS, Samman Tahhan A, Vaduganathan M et al.. “Trends in prevalence of comorbidities in heart failure clinical trials.” European journal of heart failure (2020). PMID: 32293090 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors
  95. [95]

    Bhatt DL, Steg PG, Miller M et al.. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.” The New England journal of medicine (2018). PMID: 30415628 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  96. [96]

    Fischer U, Koga M, Strbian D et al.. “Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37222476 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  97. [97]

    Patel MR, Mahaffey KW, Garg J et al.. “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.” The New England journal of medicine (2011). PMID: 21830957 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  98. [98]

    Marty FM, Ljungman P, Chemaly RF et al.. “Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.” The New England journal of medicine (2017). PMID: 29211658 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  99. [99]

    Lincoff AM, Bhasin S, Flevaris P et al.. “Cardiovascular Safety of Testosterone-Replacement Therapy.” The New England journal of medicine (2023). PMID: 37326322 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  100. [100]

    Cho MS, Kang DY, Ahn JM et al.. “Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.” The New England journal of medicine (2024). PMID: 39225258 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  101. [101]

    Kirchhof P, Camm AJ, Goette A et al.. “Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 32865375 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  102. [102]

    Landmesser U, Skurk C, Kirchhof P et al.. “Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.” The New England journal of medicine (2026). PMID: 41849741 ↗

    L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Complications, Prognosis and Natural History
  103. [103]

    Kotecha D, Holmes J, Krum H et al.. “Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.” Lancet (London, England) (2014). PMID: 25193873 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  104. [104]

    Powell-Wiley TM, Poirier P, Burke LE et al.. “Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.” Circulation (2021). PMID: 33882682 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Complications
  105. [105]

    Yeghiazarians Y, Jneid H, Tietjens JR et al.. “Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association.” Circulation (2021). PMID: 34148375 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Interventional and Device Therapy, Complications
  106. [106]

    Iwasaki YK, Nishida K, Kato T et al.. “Atrial fibrillation pathophysiology: implications for management.” Circulation (2011). PMID: 22083148 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, Special Populations and Prevention
  107. [107]

    Tisdale JE, Chung MK, Campbell KB et al.. “Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.” Circulation (2020). PMID: 32929996 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
  108. [108]

    Chyou JY, Barkoudah E, Dukes JW et al.. “Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association.” Circulation (2023). PMID: 36912134 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  109. [109]

    Joynt Maddox KE, Elkind MSV, Aparicio HJ et al.. “Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association.” Circulation (2024). PMID: 38832505 ↗

    L2REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Complications
  110. [110]

    Diener HC, Hankey GJ. “Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar.” Journal of the American College of Cardiology (2020). PMID: 32299593 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention
  111. [111]

    Ricci F, De Caterina R, Fedorowski A. “Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment.” Journal of the American College of Cardiology (2015). PMID: 26271068 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  112. [112]

    Volgman AS, Nair G, Lyubarova R et al.. “Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2022). PMID: 35027110 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Clinical Presentation, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Special Populations and Prevention
  113. [113]

    Javaheri S, Javaheri S, Somers VK et al.. “Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 39293884 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
  114. [114]

    Deferm S, Bertrand PB, Verbrugge FH et al.. “Atrial Functional Mitral Regurgitation: JACC Review Topic of the Week.” Journal of the American College of Cardiology (2019). PMID: 31097168 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
  115. [115]

    Cowie MR, Linz D, Redline S et al.. “Sleep Disordered Breathing and Cardiovascular Disease: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2021). PMID: 34353537 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  116. [116]

    Lavie CJ, Milani RV, Ventura HO. “Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss.” Journal of the American College of Cardiology (2009). PMID: 19460605 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification
  117. [117]

    Haimovich JS, Kany S, Ajufo E et al.. “Outcomes and Management of Stressor-Associated Atrial Fibrillation: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2025). PMID: 40962378 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy
  118. [118]

    Turan A, Duncan A, Leung S et al.. “Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial.” Lancet (London, England) (2020). PMID: 32682483 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  119. [119]

    Holmes DR, Reddy VY, Turi ZG et al.. “Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.” Lancet (London, England) (2009). PMID: 19683639 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, History and Evolution of Treatment, Complications
  120. [120]

    Piccini JP, Caso V, Connolly SJ et al.. “Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.” Lancet (London, England) (2022). PMID: 35385695 ↗

    L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Complications
  121. [121]

    Dhont S, Bertrand PB, Erzeel J et al.. “The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial.” European journal of heart failure (2025). PMID: 40256860 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  122. [122]

    Lin AY, Dinatolo E, Metra M et al.. “Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction.” JACC. Heart failure (2021). PMID: 33714744 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors
  123. [123]

    Reichlin T, Kueffer T, Badertscher P et al.. “Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.” The New England journal of medicine (2025). PMID: 40162734 ↗

    L1TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  124. [124]

    Gaudino M, Di Franco A, Rong LQ et al.. “Postoperative atrial fibrillation: from mechanisms to treatment.” European heart journal (2023). PMID: 36721960 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  125. [125]

    Kelters IR, Koop Y, Young ME et al.. “Circadian rhythms in cardiovascular disease.” European heart journal (2025). PMID: 40663373 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  126. [126]

    Lauder L, Mahfoud F, Azizi M et al.. “Hypertension management in patients with cardiovascular comorbidities.” European heart journal (2023). PMID: 36342266 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  127. [127]

    Natale A, Mohanty S, Sanders P et al.. “Catheter ablation for atrial fibrillation: indications and future perspective.” European heart journal (2024). PMID: 39322413 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  128. [128]

    Zimerman A, Braunwald E, Steffel J et al.. “Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.” JAMA cardiology (2024). PMID: 38985461 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  129. [129]

    Alexander JH, Lydon EJ, Piccini JP et al.. “Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40136309 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  130. [130]

    Wong CX, Cheung CC, Montenegro G et al.. “Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.” JAMA (2026). PMID: 41206802 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention
  131. [131]

    Packer DL, Mark DB, Robb RA et al.. “Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.” JAMA (2019). PMID: 30874766 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  132. [132]

    Tromp J, Claggett BL, Liu J et al.. “Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.” Circulation. Heart failure (2021). PMID: 33866828 ↗

    L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment
  133. [133]

    McMurray JJV, Wheeler DC, Stefánsson BV et al.. “Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.” JACC. Heart failure (2021). PMID: 34446370 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  134. [134]

    Kondo T, Campbell R, Jhund PS et al.. “Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.” JACC. Heart failure (2024). PMID: 38904646 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  135. [135]

    van Veldhuisen DJ, Rienstra M, Mosterd A et al.. “Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial.” European journal of heart failure (2024). PMID: 39212246 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  136. [136]

    Lund LH, James S, DeVore AD et al.. “The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design.” European journal of heart failure (2024). PMID: 39282788 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  137. [137]

    Kim D, Shim J, Choi EK et al.. “Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial.” JAMA (2025). PMID: 40886309 ↗

    L1TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  138. [138]

    Nayak SS, Amini-Salehi E, Letafatkar N et al.. “Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 42414231 ↗

    L1SR_MA_RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  139. [139]

    Schnabel RB, Yin X, Gona P et al.. “50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study.” Lancet (London, England) (2015). PMID: 25960110 ↗

    L2COHORTCited in: Epidemiology and Risk Factors
  140. [140]

    Rawshani A, Sattar N, Franzén S et al.. “Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.” Lancet (London, England) (2018). PMID: 30129464 ↗

    L2COHORTCited in: Epidemiology and Risk Factors
  141. [141]

    Bielecka-Dabrowa A, Ebner N, Dos Santos MR et al.. “Cachexia, muscle wasting, and frailty in cardiovascular disease.” European journal of heart failure (2020). PMID: 32949422 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Special Populations and Prevention
  142. [142]

    Triposkiadis F, Giamouzis G, Parissis J et al.. “Reframing the association and significance of co-morbidities in heart failure.” European journal of heart failure (2016). PMID: 27358242 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Prognosis and Natural History, Special Populations and Prevention
  143. [143]

    Wang J, Huang P, Yu Q et al.. “Epilepsy and long-term risk of arrhythmias.” European heart journal (2023). PMID: 37602368 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  144. [144]

    Linz D, McEvoy RD, Cowie MR et al.. “Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review.” JAMA cardiology (2018). PMID: 29541763 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications
  145. [145]

    Redfield MM, Borlaug BA. “Heart Failure With Preserved Ejection Fraction: A Review.” JAMA (2023). PMID: 36917048 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Complications, Prognosis and Natural History
  146. [146]

    Ruberg FL, Maurer MS. “Cardiac Amyloidosis Due to Transthyretin Protein: A Review.” JAMA (2024). PMID: 38441582 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Complications, Prognosis and Natural History
  147. [147]

    Douketis JD, Spyropoulos AC. “Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review.” JAMA (2024). PMID: 39133476 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  148. [148]

    Chaker L, Papaleontiou M. “Hypothyroidism: A Review.” JAMA (2025). PMID: 40900603 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Special Populations and Prevention
  149. [149]

    Packer M. “HFpEF Is the Substrate for Stroke in Obesity and Diabetes Independent of Atrial Fibrillation.” JACC. Heart failure (2019). PMID: 31706838 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  150. [150]

    Shen T, Shi C, Li G et al.. “Effects of cardiac rehabilitation on atrial fibrillation recurrence, mortality, hospitalization, and exercise capacity: a systematic review and meta-analysis.” PeerJ (2026). PMID: 42376039 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  151. [151]

    Kaisaier W, Chen Y, Dong Y et al.. “Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.” Thrombosis and haemostasis (2026). PMID: 42398953 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Interventional and Device Therapy
  152. [152]

    Chioncel O, Lainscak M, Seferovic PM et al.. “Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.” European journal of heart failure (2017). PMID: 28386917 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy
  153. [153]

    Matsumoto S, Henderson AD, Shen L et al.. “Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.” European journal of heart failure (2024). PMID: 39215677 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  154. [154]

    Vilches S, Fontana M, Gonzalez-Lopez E et al.. “Systemic embolism in amyloid transthyretin cardiomyopathy.” European journal of heart failure (2022). PMID: 35650018 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History
  155. [155]

    Niu X, Tang X, Fang X et al.. “Left Atrial Appendage Closure With Different Antithrombotic Therapies in Patients at High Bleeding Risk: A Ten-Year Cohort Study.” The Canadian journal of cardiology (2026). PMID: 42413819 ↗

    L3COHORTCited in: Epidemiology and Risk Factors, Complications, Prognosis and Natural History
  156. [156]

    Dong H, Han C, Chen Y et al.. “Accelerometer-measured physical activity fragmentation and incident cardiovascular diseases: a prospective cohort study.” Nutrition journal (2026). PMID: 42402585 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History
  157. [157]

    Ryan D, Yahav A, Barnett-Griness O et al.. “Trends in stroke risk among female and male patients with atrial fibrillation: a 20-year population-based cohort study.” Heart rhythm (2026). PMID: 42379411 ↗

    L3COHORTCited in: Epidemiology and Risk Factors
  158. [158]

    Stender BS, Eskildsen VK, Kramer A et al.. “Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 42378507 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
  159. [159]

    Song H, Gao S, Yang Z et al.. “Association between Cabrol shunt and new-onset atrial fibrillation after acute type A aortic dissection surgery: a retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 42375852 ↗

    L3COHORTCited in: Epidemiology and Risk Factors, Acute and Initial Management
  160. [160]

    Zhang X, Li Y, Li Q et al.. “Postoperative cerebral infarction after major thoracic and abdominopelvic surgery: a retrospective single-centre cohort study of incidence, risk factors, and outcomes.” BMC anesthesiology (2026). PMID: 42374193 ↗

    L3COHORTCited in: Epidemiology and Risk Factors
  161. [161]

    Said MA, Verweij N, van der Harst P. “Associations of Combined Genetic and Lifestyle Risks With Incident Cardiovascular Disease and Diabetes in the UK Biobank Study.” JAMA cardiology (2018). PMID: 29955826 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Prognosis and Natural History
  162. [162]

    Yoneda ZT, Anderson KC, Quintana JA et al.. “Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes.” JAMA cardiology (2021). PMID: 34495297 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  163. [163]

    Flynn S, Schuermans A, Uddin MM et al.. “Clonal Hematopoiesis and Incident Heart Failure.” JAMA cardiology (2026). PMID: 41206888 ↗

    L2OTHERCited in: Epidemiology and Risk Factors
  164. [164]

    Aung N, Nicholls HL, Chahal CAA et al.. “Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population.” JAMA cardiology (2024). PMID: 39196575 ↗

    L2OTHERCited in: Epidemiology and Risk Factors
  165. [165]

    Zhang C, Neuzil P, Petru J et al.. “Coronary Artery Spasm During Pulsed Field vs Radiofrequency Catheter Ablation of the Mitral Isthmus.” JAMA cardiology (2024). PMID: 38019505 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  166. [166]

    Reddy YNV, Frantz RP, Egbe AC et al.. “Phenotypic Characterization of Unclassified Pulmonary Hypertension.” Circulation. Heart failure (2026). PMID: 42318624 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
  167. [167]

    Mentias A, Desai MY, Aminian A et al.. “Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity.” Circulation. Heart failure (2024). PMID: 38275114 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  168. [168]

    Kannan L, Shaw PA, Morley MP et al.. “Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes.” Circulation. Heart failure (2018). PMID: 30562095 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy, Prognosis and Natural History
  169. [169]

    Chamberlain AM, Redfield MM, Alonso A et al.. “Atrial fibrillation and mortality in heart failure: a community study.” Circulation. Heart failure (2011). PMID: 21920917 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
  170. [170]

    Kyriakopoulos CP, Sideris K, Taleb I et al.. “Left Atrial Reverse Remodeling in Patients Supported With Durable Left Ventricular Assist Devices and Clinical Implications.” Circulation. Heart failure (2025). PMID: 40357557 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Complications, Prognosis and Natural History
  171. [171]

    Kodur N, Gunsalus P, Milinovich A et al.. “Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction.” Circulation. Heart failure (2025). PMID: 41178541 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Prognosis and Natural History
  172. [172]

    Ostrominski JW, Filippatos G, Claggett BL et al.. “Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART Analysis.” JACC. Heart failure (2025). PMID: 40505158 ↗

    L1OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  173. [173]

    Sochorová V, Kunštátová V, Osmančík P et al.. “COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial.” Circulation (2025). PMID: 40287932 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  174. [174]

    Solomon SD, Ostrominski JW, Wang X et al.. “Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.” Journal of the American College of Cardiology (2024). PMID: 39217567 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
  175. [175]

    Cleland JGF, Bunting KV, Flather MD et al.. “Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.” European heart journal (2018). PMID: 29040525 ↗

    L1SR_OBSCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Prognosis and Natural History
  176. [176]

    Segan L, Kistler PM, Nanayakkara S et al.. “Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.” European heart journal (2026). PMID: 40830055 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  177. [177]

    Pieske B, Maggioni AP, Lam CSP et al.. “Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.” European heart journal (2017). PMID: 28369340 ↗

    L1RCTCited in: Pathophysiology and Mechanism
  178. [178]

    Reddy VY, Gerstenfeld EP, Schmidt B et al.. “Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2.” Circulation (2025). PMID: 40273320 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, Complications
  179. [179]

    Marrouche NF, Brachmann J, Andresen D et al.. “Catheter Ablation for Atrial Fibrillation with Heart Failure.” The New England journal of medicine (2018). PMID: 29385358 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Interventional and Device Therapy, Prognosis and Natural History
  180. [180]

    Zhang W, Zhang S, Deng Y et al.. “Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.” The New England journal of medicine (2021). PMID: 34491661 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation
  181. [181]

    Asfar P, Meziani F, Hamel JF et al.. “High versus low blood-pressure target in patients with septic shock.” The New England journal of medicine (2014). PMID: 24635770 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation
  182. [182]

    Andrade JG, Wells GA, Deyell MW et al.. “Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 33197159 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Special Populations and Prevention
  183. [183]

    Verma A, Jiang CY, Betts TR et al.. “Approaches to catheter ablation for persistent atrial fibrillation.” The New England journal of medicine (2015). PMID: 25946280 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Interventional and Device Therapy, Special Populations and Prevention
  184. [184]

    Pluymaekers NAHA, Dudink EAMP, Luermans JGLM et al.. “Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation.” The New England journal of medicine (2019). PMID: 30883054 ↗

    L1RCTCited in: Pathophysiology and Mechanism
  185. [185]

    Voskoboinik A, Kalman JM, De Silva A et al.. “Alcohol Abstinence in Drinkers with Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 31893513 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Special Populations and Prevention
  186. [186]

    Karwath A, Bunting KV, Gill SK et al.. “Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.” Lancet (London, England) (2021). PMID: 34474011 ↗

    L1SR_OBSCited in: Pathophysiology and Mechanism
  187. [187]

    Niiranen TJ, Schnabel RB, Schutte AE et al.. “Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration.” Circulation (2025). PMID: 40127157 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup
  188. [188]

    Patel C, Yan GX, Kowey PR. “Dronedarone.” Circulation (2009). PMID: 19687370 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  189. [189]

    Chung MK, Eckhardt LL, Chen LY et al.. “Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association.” Circulation (2020). PMID: 32148086 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  190. [190]

    Bunch TJ. “Atrial Fibrillation and Dementia.” Circulation (2020). PMID: 32804567 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  191. [191]

    Ajoolabady A, Nattel S, Lip GYH et al.. “Inflammasome Signaling in Atrial Fibrillation: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2022). PMID: 35680186 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  192. [192]

    La Gerche A, Wasfy MM, Brosnan MJ et al.. “The Athlete's Heart-Challenges and Controversies: JACC Focus Seminar 4/4.” Journal of the American College of Cardiology (2022). PMID: 36075838 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Special Populations and Prevention
  193. [193]

    Farhan S, Silbiger JJ, Halperin JL et al.. “Pathophysiology, Echocardiographic Diagnosis, and Treatment of Atrial Functional Mitral Regurgitation: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2022). PMID: 36480974 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management
  194. [194]

    Cho L, Davis M, Elgendy I et al.. “Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2020). PMID: 32439010 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  195. [195]

    Newman JD, O'Meara E, Böhm M et al.. “Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38418008 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy
  196. [196]

    Appelboam A, Reuben A, Mann C et al.. “Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial.” Lancet (London, England) (2015). PMID: 26314489 ↗

    L1RCTCited in: Pathophysiology and Mechanism, History and Evolution of Treatment, Prognosis and Natural History
  197. [197]

    Filippatos G, Farmakis D, Butler J et al.. “Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.” European journal of heart failure (2023). PMID: 37062866 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  198. [198]

    Bunting KV, Champsi A, Gill SK et al.. “Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial.” European journal of heart failure (2025). PMID: 40891341 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  199. [199]

    Bavendiek U, Thomas NH, Berliner D et al.. “DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials.” European journal of heart failure (2025). PMID: 40389288 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  200. [200]

    Masri A, Barriales-Villa R, Elliott P et al.. “Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM.” European journal of heart failure (2024). PMID: 39023326 ↗

    L4RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  201. [201]

    Conners KM, Shearer JJ, Joo J et al.. “The Metabolic Vulnerability Index: A Novel Marker for Mortality Prediction in Heart Failure.” JACC. Heart failure (2023). PMID: 37480881 ↗

    L2SR_OBSCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Complications
  202. [202]

    Infeld M, Wahlberg K, Cicero J et al.. “Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial.” JAMA cardiology (2023). PMID: 36723919 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  203. [203]

    Matsumoto S, Henderson AD, Jhund PS et al.. “Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40156827 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  204. [204]

    Marcus GM, Modrow MF, Schmid CH et al.. “Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation: The I-STOP-AFib Randomized Clinical Trial.” JAMA cardiology (2022). PMID: 34775507 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  205. [205]

    Kotecha D, Bunting KV, Gill SK et al.. “Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.” JAMA (2020). PMID: 33351042 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  206. [206]

    Reddy VY, Sievert H, Halperin J et al.. “Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.” JAMA (2014). PMID: 25399274 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  207. [207]

    Saberi S, Abraham TP, Choudhury L et al.. “Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.” JACC. Heart failure (2025). PMID: 40540987 ↗

    L4RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  208. [208]

    Martens P, Augusto SN, Erzeel J et al.. “Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: Insights From CABANA.” JACC. Heart failure (2025). PMID: 40243977 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  209. [209]

    Ostrominski JW, Mc Causland FR, Claggett BL et al.. “Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial.” JACC. Heart failure (2025). PMID: 40208137 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  210. [210]

    Vaduganathan M, Claggett BL, Lam CSP et al.. “Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.” European journal of heart failure (2024). PMID: 38742248 ↗

    L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy
  211. [211]

    Bertero E, Chiti C, Schiavo MA et al.. “Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.” European journal of heart failure (2024). PMID: 38131253 ↗

    L2TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  212. [212]

    Rader F, Oręziak A, Choudhury L et al.. “Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.” JACC. Heart failure (2024). PMID: 38176782 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  213. [213]

    Ho CY, Day SM, Ashley EA et al.. “Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).” Circulation (2018). PMID: 30297972 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Interventional and Device Therapy, History and Evolution of Treatment, Prognosis and Natural History
  214. [214]

    Reddy YNV, Carter RE, Obokata M et al.. “A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.” Circulation (2018). PMID: 29792299 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Severity Staging and Risk Stratification
  215. [215]

    Turagam MK, Neuzil P, Schmidt B et al.. “Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry.” Circulation (2023). PMID: 37199171 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  216. [216]

    Yao C, Veleva T, Scott L et al.. “Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.” Circulation (2018). PMID: 29802206 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  217. [217]

    Donnan GA, Fisher M, Macleod M et al.. “Stroke.” Lancet (London, England) (2008). PMID: 18468545 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy
  218. [218]

    Piccini JP, Fauchier L. “Rhythm control in atrial fibrillation.” Lancet (London, England) (2016). PMID: 27560278 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Interventional and Device Therapy
  219. [219]

    Van Gelder IC, Rienstra M, Crijns HJ et al.. “Rate control in atrial fibrillation.” Lancet (London, England) (2016). PMID: 27560277 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Interventional and Device Therapy
  220. [220]

    Nattel S, Opie LH. “Controversies in atrial fibrillation.” Lancet (London, England) (2006). PMID: 16427496 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Interventional and Device Therapy
  221. [221]

    Schmieder RE, Hilgers KF, Schlaich MP et al.. “Renin-angiotensin system and cardiovascular risk.” Lancet (London, England) (2007). PMID: 17416265 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  222. [222]

    Dobrev D, Nattel S. “New antiarrhythmic drugs for treatment of atrial fibrillation.” Lancet (London, England) (2010). PMID: 20334907 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  223. [223]

    Watson T, Shantsila E, Lip GY. “Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited.” Lancet (London, England) (2009). PMID: 19135613 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  224. [224]

    Savarese G, von Haehling S, Butler J et al.. “Iron deficiency and cardiovascular disease.” European heart journal (2023). PMID: 36282723 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification
  225. [225]

    Zeng Z, Wang X, Pei J et al.. “Endothelial plasticity in atrial fibrosis by integrating single-cell sequencing and genetic lineage tracing.” European heart journal (2025). PMID: 40626706 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  226. [226]

    Muraru D, Badano LP, Hahn RT et al.. “Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment.” European heart journal (2024). PMID: 38441886 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  227. [227]

    Vad OB, van Vreeswijk N, Yassin AS et al.. “Atrial cardiomyopathy: markers and outcomes.” European heart journal (2026). PMID: 41092306 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification
  228. [228]

    Guo J, Zhang Z, Meng X et al.. “Atrial fibrillation catheter ablation, brain glymphatic function, and cognitive performance.” European heart journal (2025). PMID: 39981927 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy
  229. [229]

    Plitt A, McGuire DK, Giugliano RP. “Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review.” JAMA cardiology (2017). PMID: 28122078 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy
  230. [230]

    Prystowsky EN, Padanilam BJ, Fogel RI. “Treatment of Atrial Fibrillation.” JAMA (2015). PMID: 26197188 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Interventional and Device Therapy
  231. [231]

    Owan TE, Hodge DO, Herges RM et al.. “Trends in prevalence and outcome of heart failure with preserved ejection fraction.” The New England journal of medicine (2006). PMID: 16855265 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  232. [232]

    Marine JE. “Catheter ablation therapy for supraventricular arrhythmias.” JAMA (2007). PMID: 18165670 ↗

    L5CASE_REPORTCited in: Pathophysiology and Mechanism
  233. [233]

    Saadatagah S, Naderian M, Uddin M et al.. “Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1.” JAMA cardiology (2024). PMID: 38598228 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
  234. [234]

    Ramonfaur D, Buckley LF, Arthur V et al.. “High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life.” JAMA cardiology (2024). PMID: 38809565 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  235. [235]

    Chen H, Li C, Han B et al.. “Circumferential Pulmonary Vein Isolation With vs Without Additional Low-Voltage-Area Ablation in Older Patients With Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial.” JAMA cardiology (2023). PMID: 37378966 ↗

    L1OTHERCited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  236. [236]

    Mitchell GF, Vasan RS, Keyes MJ et al.. “Pulse pressure and risk of new-onset atrial fibrillation.” JAMA (2007). PMID: 17312290 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  237. [237]

    Sclafani M, Spartera M, Esmati Y et al.. “Weight Loss in Older Patients With Persistent Atrial Fibrillation: The LOSE-AF Randomized Clinical Trial.” JAMA (2026). PMID: 42160044 ↗

    L1OTHERCited in: Pathophysiology and Mechanism
  238. [238]

    Wang W, Zhang MJ, Inciardi RM et al.. “Association of Echocardiographic Measures of Left Atrial Function and Size With Incident Dementia.” JAMA (2022). PMID: 35315884 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  239. [239]

    Cappola AR, Fried LP, Arnold AM et al.. “Thyroid status, cardiovascular risk, and mortality in older adults.” JAMA (2006). PMID: 16507804 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  240. [240]

    Verbrugge FH, Reddy YNV, Attia ZI et al.. “Detection of Left Atrial Myopathy Using Artificial Intelligence-Enabled Electrocardiography.” Circulation. Heart failure (2021). PMID: 34911362 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Complications
  241. [241]

    Li B, Dong Y, Chen Y et al.. “Role of NADPH oxidase 2-derived reactive oxygen species in cardiac electrophysiological disorders.” Channels (Austin, Tex.) (2026). PMID: 42405795 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  242. [242]

    Vaughan M, Kaur B, Mehta NK. “Atrial Fibrillation Risk Management and Emerging Therapies.” Journal of clinical medicine (2026). PMID: 42355780 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  243. [243]

    Cozma D, Gaita D, Crisan S et al.. “The Oxygen Imperative: Cardiorespiratory Fitness, Dose-Dependent Exercise Thresholds, and Longevity-A Narrative Review.” Journal of clinical medicine (2026). PMID: 42355766 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, History and Evolution of Treatment
  244. [244]

    Swenson G, Fischer MA. “Leukocytes in Atrial Fibrillation: Mechanisms and Therapeutics.” American journal of physiology. Heart and circulatory physiology (2026). PMID: 42345613 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  245. [245]

    Karim S, Khan S, Somers VK. “Sleep, Neural Circulatory Control, and Cardiovascular Disease: A Mechanistic Review.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 42345098 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  246. [246]

    Wang Z, Wang Y, Shangguan W et al.. “Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations.” Frontiers in cardiovascular medicine (2026). PMID: 42344351 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  247. [247]

    Grigoriou K, Lamprou V, Antoniadis AP et al.. “Inflammasome-Driven Cardiac Fibrosis in Cardiometabolic Disease and Arrhythmias: Mechanisms, Biomarkers, and Therapeutic Targets.” Frontiers in bioscience (Landmark edition) (2026). PMID: 42411479 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  248. [248]

    Rojas SF, Khairy P. “Innovative Management of Rhythm Disorders in Adults with Congenital Heart Disease.” Methodist DeBakey cardiovascular journal (2026). PMID: 42403553 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  249. [249]

    Tokuda M, Yamashita S, Yokoyama M et al.. “Total Care Strategies in Atrial Fibrillation Practice: Lifestyle Intervention and Risk Factor Management.” Journal of cardiology (2026). PMID: 42402270 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  250. [250]

    Zheng X, Yang H, Sun H et al.. “Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations.” Clinical cardiology (2026). PMID: 42370746 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  251. [251]

    Metzner A, Willems S, Borof K et al.. “Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40737012 ↗

    L1RCTCited in: Clinical Presentation
  252. [252]

    Chatterjee NA, Chae CU, Kim E et al.. “Modifiable Risk Factors for Incident Heart Failure in Atrial Fibrillation.” JACC. Heart failure (2017). PMID: 28624486 ↗

    L2RCTCited in: Clinical Presentation
  253. [253]

    Lip GY, Tse HF, Lane DA. “Atrial fibrillation.” Lancet (London, England) (2011). PMID: 22166900 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  254. [254]

    Veselka J, Anavekar NS, Charron P. “Hypertrophic obstructive cardiomyopathy.” Lancet (London, England) (2016). PMID: 27912983 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy
  255. [255]

    Inciardi RM, Bonelli A, Biering-Sorensen T et al.. “Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment.” European journal of heart failure (2022). PMID: 35598167 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  256. [256]

    Jabbour G, Nolin-Lapalme A, Tastet O et al.. “Prediction of incident atrial fibrillation using deep learning, clinical models, and polygenic scores.” European heart journal (2024). PMID: 39217446 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification
  257. [257]

    Hess PL, Healey JS, Granger CB et al.. “The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review.” JAMA cardiology (2017). PMID: 28097334 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup
  258. [258]

    Mendelson SJ, Prabhakaran S. “Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review.” JAMA (2021). PMID: 33724327 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  259. [259]

    Hashiba M, Linz D, Frandsen R et al.. “VIR-SAAF: a study protocol for a national decentralised randomised controlled trial of home-based sleep apnoea screening in patients with atrial fibrillation in Denmark.” BMJ open (2026). PMID: 42409410 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  260. [260]

    Song J, Wang J, Wang X et al.. “Effect of the ligament of Marshall excision during minimally invasive cardiac surgery-coronary artery bypass grafting (MICS-CABG) on the prevention of postoperative new-onset atrial fibrillation (LOMEX-AF): study protocol for a randomised controlled trial.” BMJ open (2026). PMID: 42386296 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation, Acute and Initial Management, Interventional and Device Therapy, Prognosis and Natural History
  261. [261]

    Murphy D, Graby J, Hirst L et al.. “Assessing the impact of combined nutritional and physical activity interventions for patients with atrial fibrillation who are overweight: a systematic review protocol.” BMJ open (2026). PMID: 42336794 ↗

    L5SR_OBSCited in: Clinical Presentation
  262. [262]

    Lu R, Lumish HS, Hasegawa K et al.. “Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning.” European journal of heart failure (2024). PMID: 39694602 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment, Complications
  263. [263]

    Kanniyan AS, Mohammed O, Wadhwa A et al.. “Intracardiac Echocardiography Versus Transesophageal Echocardiography for Guidance of Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis of Procedural Safety and Efficacy.” Echocardiography (Mount Kisco, N.Y.) (2026). PMID: 42390195 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  264. [264]

    Boraita A, Santos-Lozano A, Heras ME et al.. “Incidence of Atrial Fibrillation in Elite Athletes.” JAMA cardiology (2018). PMID: 30383155 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  265. [265]

    Spencer-Bonilla G, Fan J, Cheng P et al.. “Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population.” JAMA cardiology (2026). PMID: 42054052 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  266. [266]

    Benfari G, Essayagh B, Tsaban G et al.. “Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome?” JACC. Heart failure (2026). PMID: 41677478 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  267. [267]

    Kahwash R, Butler J, Khan MS et al.. “Incidence of Cardiac Arrhythmias Identified by Insertable Cardiac Monitors in Patients With Symptomatic Heart Failure.” JACC. Heart failure (2025). PMID: 40602175 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  268. [268]

    Jani VP, Vaishnav J, Vungarala S et al.. “Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese HFpEF.” JACC. Heart failure (2025). PMID: 41037837 ↗

    L4OTHERCited in: Clinical Presentation
  269. [269]

    Oliva RV, Magno JDA, David-Ona DI et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Cardiovascular Disease.” Acta medica Philippina (2026). PMID: 42382937 ↗

    L1GUIDELINECited in: Clinical Presentation, Long-term Guideline-Directed Therapy
  270. [270]

    Mair J. “Clinical Gray Zones of Cardiac Troponin Interpretation in the Emergency Department: When Increased Concentrations Do Not Equal Acute Coronary Syndrome.” Journal of clinical medicine (2026). PMID: 42355612 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  271. [271]

    Curry SJ, Krist AH, Owens DK et al.. “Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement.” JAMA (2018). PMID: 30088016 ↗

    L1GUIDELINECited in: Diagnosis and Workup
  272. [272]

    Sanna T, Diener HC, Passman RS et al.. “Cryptogenic stroke and underlying atrial fibrillation.” The New England journal of medicine (2014). PMID: 24963567 ↗

    L1RCTCited in: Diagnosis and Workup
  273. [273]

    Wazni OM, Chun KRJ, Nair DG et al.. “Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation.” The New England journal of medicine (2026). PMID: 42041224 ↗

    L1RCTCited in: Diagnosis and Workup
  274. [274]

    Kirchhof P, Toennis T, Goette A et al.. “Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.” The New England journal of medicine (2023). PMID: 37622677 ↗

    L1RCTCited in: Diagnosis and Workup
  275. [275]

    Meybohm P, Bein B, Brosteanu O et al.. “A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery.” The New England journal of medicine (2015). PMID: 26436208 ↗

    L1RCTCited in: Diagnosis and Workup
  276. [276]

    Zarbock A, Ostermann M, Forni L et al.. “A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial.” Lancet (London, England) (2025). PMID: 41242333 ↗

    L1RCTCited in: Diagnosis and Workup, Special Populations and Prevention
  277. [277]

    Conen D, Ke Wang M, Popova E et al.. “Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial.” Lancet (London, England) (2023). PMID: 37640035 ↗

    L1RCTCited in: Diagnosis and Workup
  278. [278]

    Verma A, Birnie DH, Jiang C et al.. “Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.” The New England journal of medicine (2025). PMID: 41211931 ↗

    L1TRIAL_NONRANDOMCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  279. [279]

    Perez MV, Mahaffey KW, Hedlin H et al.. “Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation.” The New England journal of medicine (2019). PMID: 31722151 ↗

    L2TRIAL_NONRANDOMCited in: Diagnosis and Workup
  280. [280]

    Salem JE, Shoemaker MB, Bastarache L et al.. “Association of Thyroid Function Genetic Predictors With Atrial Fibrillation: A Phenome-Wide Association Study and Inverse-Variance Weighted Average Meta-analysis.” JAMA cardiology (2019). PMID: 30673079 ↗

    L2SR_OBSCited in: Diagnosis and Workup
  281. [281]

    Cikes M, Claggett B, Shah AM et al.. “Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.” JACC. Heart failure (2018). PMID: 30007557 ↗

    L2RCTCited in: Diagnosis and Workup
  282. [282]

    Sachdev PS, Bentvelzen AC, Gustafson D et al.. “Vascular Cognitive Impairment and Dementia: Clinical Features, Neuropathology, and Biomarkers.” Journal of the American College of Cardiology (2026). PMID: 41498479 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup
  283. [283]

    Shinzato K, Takahashi Y, Yamaguchi T et al.. “Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation.” European heart journal (2025). PMID: 40392565 ↗

    L4OTHERCited in: Diagnosis and Workup
  284. [284]

    Wang B, Cai H, Wu Y et al.. “Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2026). PMID: 42405627 ↗

    L1RCTCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  285. [285]

    Attia ZI, Noseworthy PA, Lopez-Jimenez F et al.. “An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction.” Lancet (London, England) (2019). PMID: 31378392 ↗

    L3OTHERCited in: Diagnosis and Workup
  286. [286]

    Lip GY, Tse HF. “Management of atrial fibrillation.” Lancet (London, England) (2007). PMID: 17707756 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Interventional and Device Therapy, Special Populations and Prevention
  287. [287]

    Kirchhof P. “The future of atrial fibrillation management: integrated care and stratified therapy.” Lancet (London, England) (2017). PMID: 28460828 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Interventional and Device Therapy
  288. [288]

    Martens P, Olivotto I, Garcia-Pavia P et al.. “Comprehensive evaluation of hypertrophic cardiomyopathy: European Journal of Heart Failure expert consensus document.” European journal of heart failure (2026). PMID: 41818712 ↗

    L5OTHERCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy
  289. [289]

    Harada T, Reddy YNV, Sorimachi H et al.. “Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction.” European journal of heart failure (2025). PMID: 40977275 ↗

    L4OTHERCited in: Diagnosis and Workup
  290. [290]

    Chang KC, Lin TT, Wang TC et al.. “Fibrosis-4 index reflects the severity of tricuspid regurgitation and patient prognosis in atrial fibrillation.” European journal of heart failure (2025). PMID: 40660086 ↗

    L3OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
  291. [291]

    Venneri L, Aimo A, Porcari A et al.. “Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis.” European journal of heart failure (2025). PMID: 41098006 ↗

    L3OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
  292. [292]

    Barbarossa A, Coraducci F, Nicolini E et al.. “Efficacy and safety of transcatheter left atrial appendage closure guided by transoesophageal echocardiography using standard and micro TEE probes: a single-center retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 42344357 ↗

    L4COHORTCited in: Diagnosis and Workup
  293. [293]

    Benjamin EJ, Thomas KL, Go AS et al.. “Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report.” JAMA cardiology (2023). PMID: 36478155 ↗

    L5OTHERCited in: Diagnosis and Workup
  294. [294]

    Mannina C, Ito K, Jin Z et al.. “Association of Left Atrial Strain With Ischemic Stroke Risk in Older Adults.” JAMA cardiology (2023). PMID: 36753086 ↗

    L2OTHERCited in: Diagnosis and Workup, Special Populations and Prevention
  295. [295]

    Kent DM, Wang AY. “Patent Foramen Ovale and Stroke: A Review.” JAMA (2025). PMID: 40720119 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Acute and Initial Management, History and Evolution of Treatment, Complications
  296. [296]

    Marrouche NF, Wilber D, Hindricks G et al.. “Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study.” JAMA (2014). PMID: 24496537 ↗

    L2OTHERCited in: Diagnosis and Workup, Interventional and Device Therapy
  297. [297]

    Herrmann FEM, Jeppsson A, Kirov H et al.. “Long-Term Continuous Monitoring of New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting.” JAMA (2025). PMID: 41065638 ↗

    L2OTHERCited in: Diagnosis and Workup
  298. [298]

    Rørth R, Jhund PS, Yilmaz MB et al.. “Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.” Circulation. Heart failure (2020). PMID: 32065760 ↗

    L2OTHERCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  299. [299]

    Qin H, Tromp J, Ter Maaten JM et al.. “Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women.” JACC. Heart failure (2024). PMID: 39708029 ↗

    L2OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment
  300. [300]

    Cikes M, Planinc I, Claggett B et al.. “Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.” JACC. Heart failure (2022). PMID: 35483796 ↗

    L2OTHERCited in: Diagnosis and Workup
  301. [301]

    King M, Martinez A, Abbruzzese S et al.. “Pulmonary Hypertension in Systemic Lupus Erythematosus Among Black and Hispanic Patients: An Observational Cohort Study.” Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2026). PMID: 42358118 ↗

    L2COHORTCited in: Diagnosis and Workup
  302. [302]

    Du H, Zeng L, Pu X. “Right atrial appendage thrombosis after percutaneous left atrial appendage occlusion: a case report.” Frontiers in cardiovascular medicine (2026). PMID: 42395878 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  303. [303]

    Shi G, Gu J, Duan Z et al.. “Anatomical and Imaging Predictors of Peri-Device Leak Following Left Atrial Appendage Closure Using the LAmbre Device: A Comparative Study of CCTA and TEE.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 42415236 ↗

    L2OTHERCited in: Diagnosis and Workup
  304. [304]

    Shi Q, Gao Y, Chen D et al.. “The HFpEF-ABA score predicts adverse cardiac remodelling and incident heart failure: a UK biobank study.” ESC heart failure (2026). PMID: 42413069 ↗

    L2OTHERCited in: Diagnosis and Workup
  305. [305]

    Chen JC, Liu KW, Huang YN et al.. “Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.” Therapeutic advances in endocrinology and metabolism (2026). PMID: 42404804 ↗

    L2OTHERCited in: Diagnosis and Workup
  306. [306]

    Schulz A, Maron MS, Peng LW et al.. “Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy.” Journal of the American Heart Association (2026). PMID: 42396815 ↗

    L2OTHERCited in: Diagnosis and Workup
  307. [307]

    Mansour L, Rasmeehirun P, L'Official G et al.. “Severe tricuspid regurgitation is a congestion-driven cardiorenal disease: A longitudinal study defining a right heart failure phenotype.” International journal of cardiology (2026). PMID: 42392510 ↗

    L2OTHERCited in: Diagnosis and Workup
  308. [308]

    Miao Q, Xue W, Lu X et al.. “Causal mitochondrial signatures in atrial fibrillation: Insights from integrated multi-omics and multi-faceted approaches.” Heart rhythm (2026). PMID: 42392476 ↗

    L2OTHERCited in: Diagnosis and Workup
  309. [309]

    Ahmed O, O'Driscoll J, Saliu D et al.. “Left Atrial Mechanical Function Following Hybrid Epicardial-Endocardial Versus Endocardial Catheter Ablation: A Randomized Mechanistic Trial.” Heart rhythm (2026). PMID: 42392470 ↗

    L1OTHERCited in: Diagnosis and Workup
  310. [310]

    Aulin J, Sjölin K, Lindbäck J et al.. “Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation.” Circulation (2024). PMID: 39045686 ↗

    L2RCTCited in: Severity Staging and Risk Stratification
  311. [311]

    Tang GHL, Hahn RT, Whisenant BK et al.. “Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort.” Journal of the American College of Cardiology (2024). PMID: 39471883 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, Prognosis and Natural History
  312. [312]

    Lopes RD, Granger CB, Wojdyla DM et al.. “Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA.” Journal of the American College of Cardiology (2024). PMID: 39019530 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  313. [313]

    Lip GY, Frison L, Halperin JL et al.. “Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.” Journal of the American College of Cardiology (2010). PMID: 21111555 ↗

    L2RCTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
  314. [314]

    Thyregod HG, Steinbrüchel DA, Ihlemann N et al.. “Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial.” Journal of the American College of Cardiology (2015). PMID: 25787196 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  315. [315]

    Benz AP, Hohnloser SH, Eikelboom JW et al.. “Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation.” European heart journal (2023). PMID: 37038327 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment, Prognosis and Natural History
  316. [316]

    Mack MJ, Leon MB, Thourani VH et al.. “Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.” The New England journal of medicine (2019). PMID: 30883058 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, Interventional and Device Therapy
  317. [317]

    Reardon MJ, Van Mieghem NM, Popma JJ et al.. “Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients.” The New England journal of medicine (2017). PMID: 28304219 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  318. [318]

    Whitlock RP, Belley-Cote EP, Paparella D et al.. “Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke.” The New England journal of medicine (2021). PMID: 33999547 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  319. [319]

    Zannad F, Anker SD, Byra WM et al.. “Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.” The New England journal of medicine (2018). PMID: 30146935 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  320. [320]

    Friberg L, Rosenqvist M, Lip GY. “Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.” European heart journal (2012). PMID: 22246443 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  321. [321]

    Hijazi Z, Oldgren J, Lindbäck J et al.. “The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.” Lancet (London, England) (2016). PMID: 27056738 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  322. [322]

    Lopes RD, Al-Khatib SM, Wallentin L et al.. “Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.” Lancet (London, England) (2012). PMID: 23036896 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  323. [323]

    Mant J, Hobbs FD, Fletcher K et al.. “Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.” Lancet (London, England) (2007). PMID: 17693178 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
  324. [324]

    Connolly S, Pogue J, Hart R et al.. “Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.” Lancet (London, England) (2006). PMID: 16765759 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  325. [325]

    Mega JL, Walker JR, Ruff CT et al.. “Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.” Lancet (London, England) (2015). PMID: 25769357 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  326. [326]

    Myhre PL, Vaduganathan M, Claggett BL et al.. “Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.” JAMA cardiology (2018). PMID: 30140899 ↗

    L2RCTCited in: Severity Staging and Risk Stratification
  327. [327]

    Abed HS, Wittert GA, Leong DP et al.. “Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.” JAMA (2013). PMID: 24240932 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  328. [328]

    Freund Y, Cachanado M, Delannoy Q et al.. “Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial.” JAMA (2020). PMID: 33201202 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
  329. [329]

    Čelutkienė J, Čerlinskaitė-Bajorė K, Cotter G et al.. “Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial.” Circulation. Heart failure (2024). PMID: 38445950 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  330. [330]

    Santos AB, Roca GQ, Claggett B et al.. “Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.” Circulation. Heart failure (2016). PMID: 27056882 ↗

    L2RCTCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment
  331. [331]

    Lee DS, Hardy J, Yee R et al.. “Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators.” Circulation. Heart failure (2015). PMID: 26224792 ↗

    L2RCTCited in: Severity Staging and Risk Stratification, Interventional and Device Therapy, Prognosis and Natural History, Special Populations and Prevention
  332. [332]

    Zonneveld LEEC, Pandey A, Beldhuis IE et al.. “Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.” JACC. Heart failure (2026). PMID: 41893376 ↗

    L2RCTCited in: Severity Staging and Risk Stratification
  333. [333]

    Mamas MA, Caldwell JC, Chacko S et al.. “A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure.” European journal of heart failure (2009). PMID: 19553398 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification
  334. [334]

    Schnabel RB, Sullivan LM, Levy D et al.. “Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.” Lancet (London, England) (2009). PMID: 19249635 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  335. [335]

    Ludwig S, Klimek M, Bay B et al.. “Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk: An Individual Participant Data Meta-Analysis.” JAMA cardiology (2025). PMID: 40884787 ↗

    L1SR_OBSCited in: Severity Staging and Risk Stratification, Interventional and Device Therapy
  336. [336]

    Hsu JC, Maddox TM, Kennedy KF et al.. “Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry.” JAMA cardiology (2016). PMID: 27437655 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification
  337. [337]

    Kristensen SL, Mogensen UM, Jhund PS et al.. “N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.” Circulation. Heart failure (2019). PMID: 30871349 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification, Prognosis and Natural History
  338. [338]

    Park H, Norby FL, Kim D et al.. “Proteomic Signatures for Risk Prediction of Atrial Fibrillation.” Circulation (2025). PMID: 40401370 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  339. [339]

    Khurshid S, Friedman S, Reeder C et al.. “ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation.” Circulation (2021). PMID: 34743566 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  340. [340]

    Dardari ZA, Yao Z, Zhang J et al.. “Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.” Circulation (2026). PMID: 41674444 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  341. [341]

    Aggarwal R, Ruff CT, Virdone S et al.. “Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.” Circulation (2023). PMID: 37621213 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  342. [342]

    Siontis KC, Zhang X, Eckard A et al.. “Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.” Circulation (2018). PMID: 29954737 ↗

    L3OTHERCited in: Severity Staging and Risk Stratification
  343. [343]

    Beeche C, Zhao B, Tavolinejad H et al.. “Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences.” Circulation (2025). PMID: 40671674 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  344. [344]

    Mohammadi-Shemirani P, Chong M, Narula S et al.. “Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study.” Journal of the American College of Cardiology (2022). PMID: 35450575 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  345. [345]

    Chang SH, Kuo CF, Chou IJ et al.. “Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study.” JAMA cardiology (2017). PMID: 28678986 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  346. [346]

    Segan L, Canovas R, Nanayakkara S et al.. “New-onset atrial fibrillation prediction: the HARMS2-AF risk score.” European heart journal (2023). PMID: 37350480 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  347. [347]

    Wang N, Sun Y, Zhang H et al.. “Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.” European heart journal (2021). PMID: 34374755 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  348. [348]

    Phillips KP, Nair DG, Boersma LVA et al.. “Percutaneous left atrial appendage closure following catheter ablation therapy of atrial fibrillation: outcomes stratified by bleeding risk - a sub-analysis of the OPTION study.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 42225271 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  349. [349]

    Wang Y, Ding C, Liu Y et al.. “Bidirectional association between COPD and AF: a systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42403902 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  350. [350]

    Freedman B, Potpara TS, Lip GY. “Stroke prevention in atrial fibrillation.” Lancet (London, England) (2016). PMID: 27560276 ↗

    L5REVIEW_NARRATIVECited in: Severity Staging and Risk Stratification
  351. [351]

    Tawfiq E, Selak V, Elwood JM et al.. “Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study.” Lancet (London, England) (2023). PMID: 36702148 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  352. [352]

    Tuna MA, Rothwell PM. “Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis.” Lancet (London, England) (2021). PMID: 33676629 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  353. [353]

    Cai A, Qiu W, Zhou Y et al.. “Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database-Heart Failure Center Registry.” European journal of heart failure (2022). PMID: 36054149 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  354. [354]

    Gao Q, Wang Y, Zhao Y et al.. “Risk of Stroke, Thromboembolism and Mortality in Atrial Fibrillation Patients Across Different Stages and Types of Heart Failure: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42278998 ↗

    L3COHORTCited in: Severity Staging and Risk Stratification
  355. [355]

    Katarzyna G, Ewa D, Mateusz W et al.. “Risk-score performance for detecting transthyretin cardiac amyloidosis in severe aortic stenosis: a prospective cohort study.” Frontiers in cardiovascular medicine (2026). PMID: 42257036 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  356. [356]

    Vad OB, Monfort LM, Paludan-Müller C et al.. “Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk.” JAMA cardiology (2024). PMID: 38922602 ↗

    L3OTHERCited in: Severity Staging and Risk Stratification
  357. [357]

    Zhang R, Kim MS, Yin W et al.. “Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.” JAMA cardiology (2025). PMID: 41060636 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  358. [358]

    Butt JH, Olesen JB, Gundlund A et al.. “Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Left-Sided Heart Valve Surgery.” JAMA cardiology (2019). PMID: 31596426 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  359. [359]

    Abdel-Qadir H, Singh SM, Pang A et al.. “Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors.” JAMA cardiology (2021). PMID: 34009232 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  360. [360]

    Ellervik C, Roselli C, Christophersen IE et al.. “Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A Mendelian Randomization Study.” JAMA cardiology (2019). PMID: 30673084 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  361. [361]

    Själander S, Holmqvist F, Smith JG et al.. “Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation.” JAMA cardiology (2017). PMID: 27893055 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  362. [362]

    Honigberg MC, Zekavat SM, Aragam K et al.. “Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.” JAMA (2019). PMID: 31738818 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  363. [363]

    Walkey AJ, Wiener RS, Ghobrial JM et al.. “Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis.” JAMA (2011). PMID: 22081378 ↗

    L3OTHERCited in: Severity Staging and Risk Stratification
  364. [364]

    Xian Y, O'Brien EC, Liang L et al.. “Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation.” JAMA (2017). PMID: 28291892 ↗

    L3OTHERCited in: Severity Staging and Risk Stratification
  365. [365]

    Melgaard L, Gorst-Rasmussen A, Lane DA et al.. “Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.” JAMA (2015). PMID: 26318604 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  366. [366]

    Zile MR, Kahwash R, Sarkar S et al.. “A Novel Heart Failure Diagnostic Risk Score Using a Minimally Invasive Subcutaneous Insertable Cardiac Monitor.” JACC. Heart failure (2023). PMID: 37943225 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  367. [367]

    Zile MR, Kahwash R, Sarkar S et al.. “Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure.” JACC. Heart failure (2023). PMID: 36752485 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  368. [368]

    Tada A, Doi S, Harada T et al.. “Autoimmune Disorders in Heart Failure With Preserved Ejection Fraction.” JACC. Heart failure (2024). PMID: 38819353 ↗

    L4OTHERCited in: Severity Staging and Risk Stratification
  369. [369]

    Pandey A, Kim S, Moore C et al.. “Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation.” JACC. Heart failure (2017). PMID: 28034376 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  370. [370]

    Dastjerdi P, Tavakoli K, Narimani-Javid R et al.. “Functional mitral valve regurgitation outcomes by treatment modality: a systematic review and meta-analysis of reconstructed survival data.” BMC cardiovascular disorders (2026). PMID: 42321618 ↗

    L1SR_OBSCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment
  371. [371]

    Du Y, Yang F, Liu Y. “Correlation of composite inflammatory indices and homocysteine with the severity of acute ischemic stroke: A retrospective study.” Medicine (2026). PMID: 42260856 ↗

    L3COHORTCited in: Severity Staging and Risk Stratification
  372. [372]

    Chen H, Lakhani DA, Salim HA et al.. “MAD-MT Score: A Tool to Optimize Patient Selection for Mechanical Thrombectomy in Distal Vessel Occlusions.” Stroke (2026). PMID: 42417042 ↗

    L3OTHERCited in: Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy
  373. [373]

    Rashedi S, Keykhaei M, Sato A et al.. “Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.” Journal of the American College of Cardiology (2025). PMID: 39918465 ↗

    L1SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  374. [374]

    Benali K, Khairy P, Hammache N et al.. “Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation.” Journal of the American College of Cardiology (2023). PMID: 37225362 ↗

    L1SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications
  375. [375]

    Dehbi HM, Fischer U, Åsberg S et al.. “Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST).” Lancet (London, England) (2025). PMID: 40570866 ↗

    L1SR_MA_RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History, Special Populations and Prevention
  376. [376]

    Reddy VY, Calkins H, Mansour M et al.. “Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the AdmIRE Pivotal Trial.” Circulation (2024). PMID: 39258362 ↗

    L4TRIAL_NONRANDOMCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  377. [377]

    Granger CB, Alexander JH, McMurray JJ et al.. “Apixaban versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2011). PMID: 21870978 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  378. [378]

    Connolly SJ, Sharma M, Cohen AT et al.. “Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.” The New England journal of medicine (2024). PMID: 38749032 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  379. [379]

    Ruff CT, Giugliano RP, Braunwald E et al.. “Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.” Lancet (London, England) (2013). PMID: 24315724 ↗

    L1SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  380. [380]

    Nogueira RG, Jovin TG, Liu X et al.. “Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis.” Lancet (London, England) (2024). PMID: 39674187 ↗

    L1SR_OBSCited in: Acute and Initial Management, Prognosis and Natural History
  381. [381]

    Veltkamp R, Korompoki E, Harvey KH et al.. “Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.” Lancet (London, England) (2025). PMID: 40023176 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  382. [382]

    Piccini JP, Patel MR, Steffel J et al.. “Asundexian versus Apixaban in Patients with Atrial Fibrillation.” The New England journal of medicine (2024). PMID: 39225267 ↗

    L1TRIAL_NONRANDOMCited in: Acute and Initial Management
  383. [383]

    Kistler PM, Chieng D, Sugumar H et al.. “Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial.” JAMA (2023). PMID: 36625809 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  384. [384]

    Mato AR, Shah NN, Jurczak W et al.. “Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.” Lancet (London, England) (2021). PMID: 33676628 ↗

    L4TRIAL_NONRANDOMCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  385. [385]

    Wang M, Rule S, Zinzani PL et al.. “Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.” Lancet (London, England) (2017). PMID: 29241979 ↗

    L4TRIAL_NONRANDOMCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  386. [386]

    Bavendiek U, Berliner D, Dávila LA et al.. “Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.” European journal of heart failure (2019). PMID: 30892806 ↗

    L5TRIAL_NONRANDOMCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  387. [387]

    Deftereos SG, Beerkens FJ, Shah B et al.. “Colchicine in Cardiovascular Disease: In-Depth Review.” Circulation (2021). PMID: 34965168 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
  388. [388]

    Verma A, Haines DE, Boersma LV et al.. “Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial.” Circulation (2023). PMID: 36877118 ↗

    L4OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  389. [389]

    Reddy VY, Neuzil P, Koruth JS et al.. “Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation.” Journal of the American College of Cardiology (2019). PMID: 31085321 ↗

    L4OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  390. [390]

    Imazio M, Nidorf M. “Colchicine and the heart.” European heart journal (2021). PMID: 33961006 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management
  391. [391]

    Landmesser U, Skurk C, Tzikas A et al.. “Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives.” European heart journal (2024). PMID: 39027946 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  392. [392]

    Becher N, Metzner A, Toennis T et al.. “Atrial fibrillation burden: a new outcome predictor and therapeutic target.” European heart journal (2024). PMID: 38953776 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
  393. [393]

    Cueva-Cañola LE, Tapia C, Torres Castro AP et al.. “Colchicine in cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.” Medicina clinica (2026). PMID: 42413351 ↗

    L1SR_MA_RCTCited in: Acute and Initial Management, Complications
  394. [394]

    Okumura Y, Tokuda M, Nagashima K et al.. “PERSIST-PWI trial: Rationale and design of a multicenter randomized controlled trial comparing pulmonary vein isolation alone with pulmonary vein isolation plus posterior wall isolation using pulsed field ablation in patients with persistent atrial fibrillation.” Heart rhythm O2 (2026). PMID: 42369805 ↗

    L5RCTCited in: Acute and Initial Management, Interventional and Device Therapy
  395. [395]

    Kochkarian T, Ismail A, Chaabo O et al.. “Personalized Antithrombotic Therapy After Percutaneous Coronary Intervention: A Systematic Review of Risk-Stratified Approaches.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 42410742 ↗

    L1SR_OBSCited in: Acute and Initial Management, History and Evolution of Treatment
  396. [396]

    Bikdeli B, Zahedi Tajrishi F, Sadeghipour P et al.. “Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.” JAMA cardiology (2022). PMID: 35648414 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  397. [397]

    Burashnikov A, Di Diego JM, Barajas-Martínez H et al.. “Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.” Circulation. Heart failure (2014). PMID: 24874201 ↗

    L5OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  398. [398]

    Shah P, Zheng Y, Pieske B et al.. “Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.” Circulation. Heart failure (2025). PMID: 41058565 ↗

    L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
  399. [399]

    Ezekowitz JA, Hu J, Delgado D et al.. “Acute heart failure: perspectives from a randomized trial and a simultaneous registry.” Circulation. Heart failure (2012). PMID: 23032196 ↗

    L2OTHERCited in: Acute and Initial Management
  400. [400]

    Avula V, Sharma G, Kosiborod MN et al.. “SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.” JACC. Heart failure (2023). PMID: 37897456 ↗

    L3OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  401. [401]

    Birnie DH, Healey JS, Wells GA et al.. “Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).” European heart journal (2018). PMID: 30462279 ↗

    L1RCTCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Prognosis and Natural History
  402. [402]

    Gaudino M, Sanna T, Ballman KV et al.. “Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial.” Lancet (London, England) (2021). PMID: 34788640 ↗

    L1RCTCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  403. [403]

    Tucker WJ, Fegers-Wustrow I, Halle M et al.. “Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4.” Journal of the American College of Cardiology (2022). PMID: 36075680 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy, Special Populations and Prevention
  404. [404]

    Bejjani A, Khairani CD, Assi A et al.. “When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38233019 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy, Complications
  405. [405]

    Doherty JU, Gluckman TJ, Hucker WJ et al.. “2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force.” Journal of the American College of Cardiology (2017). PMID: 28081965 ↗

    L5OTHERCited in: Long-term Guideline-Directed Therapy
  406. [406]

    Wazni OM, Saliba WI, Nair DG et al.. “Left Atrial Appendage Closure after Ablation for Atrial Fibrillation.” The New England journal of medicine (2024). PMID: 39555822 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy
  407. [407]

    Reddy VY, Gerstenfeld EP, Natale A et al.. “Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37634148 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy
  408. [408]

    Thangjui S, Knutsen K, Hollowell B et al.. “Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42370998 ↗

    L3COHORTCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  409. [409]

    Huffman MD, Malaisrie SC, Karmali KN. “Concomitant Atrial Fibrillation Surgery for People Undergoing Cardiac Surgery.” JAMA cardiology (2017). PMID: 28196179 ↗

    L1REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy
  410. [410]

    Kent DM, Saver JL, Kasner SE et al.. “Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke.” JAMA (2021). PMID: 34905030 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy, Special Populations and Prevention
  411. [411]

    Kamel H, Longstreth WT, Tirschwell DL et al.. “Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial.” JAMA (2024). PMID: 38324415 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy
  412. [412]

    Karthikeyan G, Ntsekhe M, Islam S et al.. “Mortality and Morbidity in Adults With Rheumatic Heart Disease.” JAMA (2024). PMID: 38837131 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  413. [413]

    Zheng J, Heidenreich PA, Kohsaka S et al.. “Long-Term Outcomes of Early Coronary Artery Disease Testing After New-Onset Heart Failure.” Circulation. Heart failure (2023). PMID: 37212148 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  414. [414]

    Keefe JA, Garber R, McCauley MD et al.. “Tachycardia and Atrial Fibrillation-Related Cardiomyopathies: Potential Mechanisms and Current Therapies.” JACC. Heart failure (2024). PMID: 38206235 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications
  415. [415]

    Halahakone U, Borg SJ, Senanayake S et al.. “Health Care Workers' Preferences in the Delivery of Atrial Fibrillation Screening: A Systematic Review.” Heart, lung & circulation (2026). PMID: 42392917 ↗

    L5SR_OBSCited in: Long-term Guideline-Directed Therapy
  416. [416]

    Topriceanu CC, Balakrishnan ID, Vissing CR et al.. “Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry.” Journal of the American College of Cardiology (2026). PMID: 42417692 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  417. [417]

    Ahmed T, Mathew RO, Elkind MSV et al.. “PREVENT Equations: Implications for Stroke Prevention.” Stroke (2026). PMID: 42417034 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy
  418. [418]

    He M, Erickson KF, Kassem H et al.. “Safety and Effectiveness of Apixaban Versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation.” American journal of nephrology (2026). PMID: 42412715 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  419. [419]

    Menichelli D, Cormaci VMD, Gazzaniga G et al.. “Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.” Cancer (2026). PMID: 42411384 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  420. [420]

    Steffel J, Verhamme P, Potpara TS et al.. “The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.” European heart journal (2018). PMID: 29562325 ↗

    L1GUIDELINECited in: Interventional and Device Therapy, History and Evolution of Treatment, Complications
  421. [421]

    Prabhu S, Taylor AJ, Costello BT et al.. “Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.” Journal of the American College of Cardiology (2017). PMID: 28855115 ↗

    L1RCTCited in: Interventional and Device Therapy
  422. [422]

    Reddy VY, Mansour M, Calkins H et al.. “Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden.” Journal of the American College of Cardiology (2024). PMID: 38864538 ↗

    L1RCTCited in: Interventional and Device Therapy
  423. [423]

    Cappato R, Marchlinski FE, Hohnloser SH et al.. “Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.” European heart journal (2015). PMID: 25975659 ↗

    L1RCTCited in: Interventional and Device Therapy, History and Evolution of Treatment
  424. [424]

    Brignole M, Pentimalli F, Palmisano P et al.. “AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial.” European heart journal (2021). PMID: 34453840 ↗

    L1RCTCited in: Interventional and Device Therapy, History and Evolution of Treatment, Prognosis and Natural History
  425. [425]

    Reddy VY, Anic A, Koruth J et al.. “Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation.” Journal of the American College of Cardiology (2020). PMID: 32854842 ↗

    L4TRIAL_NONRANDOMCited in: Interventional and Device Therapy
  426. [426]

    Fudim M, Dalgaard F, Friedman DJ et al.. “Comorbidities and clinical response to cardiac resynchronization therapy: Patient-level meta-analysis from eight clinical trials.” European journal of heart failure (2023). PMID: 37671601 ↗

    L2TRIAL_NONRANDOMCited in: Interventional and Device Therapy
  427. [427]

    Calkins H, Willems S, Gerstenfeld EP et al.. “Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.” The New England journal of medicine (2017). PMID: 28317415 ↗

    L1RCTCited in: Interventional and Device Therapy
  428. [428]

    Kuck KH, Brugada J, Fürnkranz A et al.. “Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.” The New England journal of medicine (2016). PMID: 27042964 ↗

    L1RCTCited in: Interventional and Device Therapy
  429. [429]

    Healey JS, Connolly SJ, Gold MR et al.. “Subclinical atrial fibrillation and the risk of stroke.” The New England journal of medicine (2012). PMID: 22236222 ↗

    L1RCTCited in: Interventional and Device Therapy
  430. [430]

    Yasuda S, Kaikita K, Akao M et al.. “Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.” The New England journal of medicine (2019). PMID: 31475793 ↗

    L1RCTCited in: Interventional and Device Therapy
  431. [431]

    Chatterjee NA, Upadhyay GA, Ellenbogen KA et al.. “Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode.” European journal of heart failure (2012). PMID: 22436544 ↗

    L2SR_OBSCited in: Interventional and Device Therapy
  432. [432]

    Vranckx P, Valgimigli M, Eckardt L et al.. “Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.” Lancet (London, England) (2019). PMID: 31492505 ↗

    L1RCTCited in: Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  433. [433]

    Gouda P, Alemayehu W, Voors AA et al.. “Implantable cardioverter-defibrillators in ischaemic versus non-ischaemic heart failure: Insights from the VICTORIA trial.” European journal of heart failure (2025). PMID: 40539883 ↗

    L1RCTCited in: Interventional and Device Therapy
  434. [434]

    Sciacca V, Sohns C, Crijns HJGM et al.. “Effects of atrial fibrillation ablation on arrhythmia burden and ventricular function in end-stage heart failure: Lessons from CASTLE-HTx.” European journal of heart failure (2024). PMID: 39444312 ↗

    L1RCTCited in: Interventional and Device Therapy
  435. [435]

    Amit G, Nyong J, Morillo CA. “Efficacy of Catheter Ablation for Nonparoxysmal Atrial Fibrillation.” JAMA cardiology (2017). PMID: 28423144 ↗

    L2SR_OBSCited in: Interventional and Device Therapy
  436. [436]

    Turagam MK, Musikantow D, Whang W et al.. “Assessment of Catheter Ablation or Antiarrhythmic Drugs for First-line Therapy of Atrial Fibrillation: A Meta-analysis of Randomized Clinical Trials.” JAMA cardiology (2021). PMID: 33909022 ↗

    L2SR_OBSCited in: Interventional and Device Therapy
  437. [437]

    Lopes RD, Hong H, Harskamp RE et al.. “Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.” JAMA cardiology (2020). PMID: 32101251 ↗

    L2SR_OBSCited in: Interventional and Device Therapy
  438. [438]

    Valderrábano M, Peterson LE, Swarup V et al.. “Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial.” JAMA (2020). PMID: 33107945 ↗

    L1RCTCited in: Interventional and Device Therapy
  439. [439]

    Al-Kaisey AM, Parameswaran R, Bryant C et al.. “Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial.” JAMA (2023). PMID: 37698564 ↗

    L1RCTCited in: Interventional and Device Therapy
  440. [440]

    Lakkireddy DR, Wilber DJ, Mittal S et al.. “Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial.” JAMA (2024). PMID: 38563835 ↗

    L1RCTCited in: Interventional and Device Therapy
  441. [441]

    Healey JS, Hohnloser SH, Exner DV et al.. “Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT).” Circulation. Heart failure (2012). PMID: 22896584 ↗

    L1RCTCited in: Interventional and Device Therapy
  442. [442]

    Birnie DH, Ha A, Higginson L et al.. “Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).” Circulation. Heart failure (2013). PMID: 23995437 ↗

    L1RCTCited in: Interventional and Device Therapy
  443. [443]

    Conraads VM, Spruit MA, Braunschweig F et al.. “Physical activity measured with implanted devices predicts patient outcome in chronic heart failure.” Circulation. Heart failure (2014). PMID: 24519908 ↗

    L1RCTCited in: Interventional and Device Therapy
  444. [444]

    Chieng D, Sugumar H, Segan L et al.. “Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial.” JACC. Heart failure (2023). PMID: 36868916 ↗

    L1RCTCited in: Interventional and Device Therapy, Prognosis and Natural History
  445. [445]

    Ivanovski M, Mrak M, Mežnar AZ et al.. “The CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.” European journal of heart failure (2025). PMID: 40920457 ↗

    L2TRIAL_NONRANDOMCited in: Interventional and Device Therapy
  446. [446]

    Reddy VY, Petru J, Funasako M et al.. “Coronary Arterial Spasm During Pulsed Field Ablation to Treat Atrial Fibrillation.” Circulation (2022). PMID: 36134574 ↗

    L5OTHERCited in: Interventional and Device Therapy
  447. [447]

    Reddy VY, Gerstenfeld EP, Schmidt B et al.. “Pulsed Field Ablation for Persistent Atrial Fibrillation: 1-Year Results of ADVANTAGE AF.” Journal of the American College of Cardiology (2025). PMID: 40306839 ↗

    L5OTHERCited in: Interventional and Device Therapy, History and Evolution of Treatment
  448. [448]

    Di Biase L, Lakkireddy DJ, Marazzato J et al.. “Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38171713 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  449. [449]

    Kanaoka K, Nishida T, Iwanaga Y et al.. “Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.” European heart journal (2024). PMID: 38117227 ↗

    L5OTHERCited in: Interventional and Device Therapy
  450. [450]

    Obokata M, Reddy YNV, Yang JH et al.. “Left Atrial Contracture or Failure to Dilate.” Circulation. Heart failure (2018). PMID: 30354368 ↗

    L4CASE_REPORTCited in: Interventional and Device Therapy
  451. [451]

    Lee G, Sanders P, Kalman JM. “Catheter ablation of atrial arrhythmias: state of the art.” Lancet (London, England) (2012). PMID: 23101718 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  452. [452]

    Verheugt FW, Granger CB. “Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.” Lancet (London, England) (2015). PMID: 25777666 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy, Special Populations and Prevention
  453. [453]

    von Stein P, Weimann J, Pfister R et al.. “Prognostic value of NT-proBNP in patients with primary mitral regurgitation undergoing transcatheter edge-to-edge repair.” European journal of heart failure (2025). PMID: 40533899 ↗

    L3OTHERCited in: Interventional and Device Therapy
  454. [454]

    Packer M. “Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment.” European journal of heart failure (2019). PMID: 31849132 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  455. [455]

    Liu LC, Damman K, Lipsic E et al.. “Heart failure highlights in 2012-2013.” European journal of heart failure (2013). PMID: 24464645 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  456. [456]

    Filippatos G, Birnie D, Gold MR et al.. “Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing.” European journal of heart failure (2017). PMID: 28708290 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  457. [457]

    Assaf A, Feng H, Bsoul M et al.. “Characterization of arrhythmia-induced cardiomyopathy using magnetic resonance imaging in patients with persistent atrial fibrillation and left ventricular systolic dysfunction - insights from DECAAF II.” European journal of heart failure (2025). PMID: 40356053 ↗

    L3OTHERCited in: Interventional and Device Therapy
  458. [458]

    von Olshausen G, Benson L, Dahlström U et al.. “Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry.” European journal of heart failure (2022). PMID: 35779270 ↗

    L2OTHERCited in: Interventional and Device Therapy
  459. [459]

    Turagam MK, Neuzil P, Schmidt B et al.. “Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation.” JAMA cardiology (2023). PMID: 37910101 ↗

    L3OTHERCited in: Interventional and Device Therapy
  460. [460]

    Fumagalli C, Maurizi N, Day SM et al.. “Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy.” JAMA cardiology (2020). PMID: 31693057 ↗

    L2OTHERCited in: Interventional and Device Therapy
  461. [461]

    Butters A, Semsarian CR, Bagnall RD et al.. “Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients With Hypertrophic Cardiomyopathy.” Circulation. Heart failure (2021). PMID: 33724884 ↗

    L3OTHERCited in: Interventional and Device Therapy
  462. [462]

    Khazanie P, Greiner MA, Al-Khatib SM et al.. “Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.” Circulation. Heart failure (2016). PMID: 27296396 ↗

    L2OTHERCited in: Interventional and Device Therapy, Special Populations and Prevention
  463. [463]

    Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G et al.. “Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy.” Circulation. Heart failure (2009). PMID: 19808323 ↗

    L3OTHERCited in: Interventional and Device Therapy
  464. [464]

    Klein L, Grau-Sepulveda MV, Bonow RO et al.. “Quality of care and outcomes in women hospitalized for heart failure.” Circulation. Heart failure (2011). PMID: 21862732 ↗

    L2OTHERCited in: Interventional and Device Therapy
  465. [465]

    Ariyaratnam JP, Mishima RS, Kadhim K et al.. “Utility and Validity of the HFA-PEFF and H2FPEF Scores in Patients With Symptomatic Atrial Fibrillation.” JACC. Heart failure (2024). PMID: 38520461 ↗

    L3OTHERCited in: Interventional and Device Therapy
  466. [466]

    Normand C, Linde C, Singh J et al.. “Indications for Cardiac Resynchronization Therapy: A Comparison of the Major International Guidelines.” JACC. Heart failure (2018). PMID: 29598935 ↗

    L5OTHERCited in: Interventional and Device Therapy
  467. [467]

    Ariyaratnam JP, Elliott AD, Mishima RS et al.. “Identification of Subclinical Heart Failure With Preserved Ejection Fraction in Patients With Symptomatic Atrial Fibrillation.” JACC. Heart failure (2023). PMID: 37676212 ↗

    L2OTHERCited in: Interventional and Device Therapy
  468. [468]

    Marques P, Travlos CK, Matias P et al.. “Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.” JACC. Heart failure (2025). PMID: 40992090 ↗

    L3OTHERCited in: Interventional and Device Therapy
  469. [469]

    Bola H, Arif A, J Hon J et al.. “Cryoballoon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: Meta-Analysis of Randomized Trials.” Pacing and clinical electrophysiology : PACE (2026). PMID: 42397058 ↗

    L1SR_OBSCited in: Interventional and Device Therapy, Prognosis and Natural History
  470. [470]

    Bacha Z, Javed J, Khan MH et al.. “Comparative effectiveness of figure-of-eight suture and manual compression for femoral venous hemostasis after atrial fibrillation ablation: A grade assessed meta-analysis.” Journal of thrombosis and thrombolysis (2026). PMID: 42384139 ↗

    L1SR_OBSCited in: Interventional and Device Therapy
  471. [471]

    Mohsen Y, Novikov I, Sabareesan S et al.. “Documented Obstructive Sleep Apnea, Cardiometabolic Phenotype, and Rhythm-Related Outcomes After Atrial Fibrillation Ablation: An Observational Cohort Study.” Journal of arrhythmia (2026). PMID: 42382280 ↗

    L3COHORTCited in: Interventional and Device Therapy
  472. [472]

    Oldgren J, Åsberg S, Hijazi Z et al.. “Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.” Circulation (2022). PMID: 36065821 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History
  473. [473]

    Joosten LPT, van Doorn S, van de Ven PM et al.. “Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.” Circulation (2023). PMID: 37634130 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  474. [474]

    Holmes DR, Kar S, Price MJ et al.. “Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.” Journal of the American College of Cardiology (2014). PMID: 24998121 ↗

    L1RCTCited in: History and Evolution of Treatment
  475. [475]

    Filippatos G, Bakris GL, Pitt B et al.. “Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.” Journal of the American College of Cardiology (2021). PMID: 34015478 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  476. [476]

    Verma S, Butler J, Borlaug BA et al.. “Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.” Journal of the American College of Cardiology (2024). PMID: 39217565 ↗

    L1RCTCited in: History and Evolution of Treatment
  477. [477]

    Papi A, Vestbo J, Fabbri L et al.. “Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.” Lancet (London, England) (2018). PMID: 29429593 ↗

    L1RCTCited in: History and Evolution of Treatment
  478. [478]

    Heerspink HJL, Kiyosue A, Wheeler DC et al.. “Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.” Lancet (London, England) (2023). PMID: 37931629 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Special Populations and Prevention
  479. [479]

    Krisai P, Belley-Cote EP, McIntyre WF et al.. “Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial.” European journal of heart failure (2024). PMID: 39586754 ↗

    L1RCTCited in: History and Evolution of Treatment
  480. [480]

    Butt JH, Docherty KF, Jhund PS et al.. “Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.” European journal of heart failure (2021). PMID: 34766424 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History
  481. [481]

    Maron BJ. “Hypertrophic cardiomyopathy: a systematic review.” JAMA (2002). PMID: 11886323 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  482. [482]

    McQuilten ZK, Thao LTP, Bick AG et al.. “Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin.” JAMA cardiology (2025). PMID: 41091476 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  483. [483]

    Yang Z, Tiemuerniyazi X, Xu F et al.. “Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 39550720 ↗

    L1RCTCited in: History and Evolution of Treatment
  484. [484]

    Siegal DM, Sticherling C, Healey JS et al.. “Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 41222953 ↗

    L1RCTCited in: History and Evolution of Treatment
  485. [485]

    Nassif ME, Windsor SL, Gosch K et al.. “Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.” Circulation. Heart failure (2023). PMID: 37203441 ↗

    L1RCTCited in: History and Evolution of Treatment
  486. [486]

    Oluleye OW, Rector TS, Win S et al.. “History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction.” Circulation. Heart failure (2014). PMID: 25225241 ↗

    L2RCTCited in: History and Evolution of Treatment, Prognosis and Natural History
  487. [487]

    Jering KS, Claggett BL, Pfeffer MA et al.. “Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.” Circulation. Heart failure (2023). PMID: 37125529 ↗

    L1RCTCited in: History and Evolution of Treatment
  488. [488]

    Zakeri R, Borlaug BA, McNulty SE et al.. “Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.” Circulation. Heart failure (2013). PMID: 24162898 ↗

    L2RCTCited in: History and Evolution of Treatment
  489. [489]

    van Diepen S, Hellkamp AS, Patel MR et al.. “Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.” Circulation. Heart failure (2013). PMID: 23723250 ↗

    L1RCTCited in: History and Evolution of Treatment
  490. [490]

    Diet F, Erdmann E. “Thromboembolism in heart failure: who should be treated?” European journal of heart failure (2000). PMID: 11113711 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  491. [491]

    Mi X, Wang T, Ye W et al.. “Impact of hypertension history and blood pressure parameters on cognitive impairment in patients with atrial fibrillation: a systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42311763 ↗

    L3SR_OBSCited in: History and Evolution of Treatment
  492. [492]

    Khraisat O, Messer T, Harmouch K et al.. “Discontinuation and non-publication of atrial fibrillation clinical trials: A retrospective analysis of 538 trials.” International journal of cardiology. Heart & vasculature (2026). PMID: 42291445 ↗

    L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  493. [493]

    Elshazly MB, Wilkoff BL, Tarakji K et al.. “Exercise Ventricular Rates, Cardiopulmonary Exercise Performance, and Mortality in Patients With Heart Failure With Atrial Fibrillation.” Circulation. Heart failure (2021). PMID: 33478244 ↗

    L2OTHERCited in: History and Evolution of Treatment
  494. [494]

    Parikh VN, Caleshu C, Reuter C et al.. “Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy.” Circulation. Heart failure (2019). PMID: 30871351 ↗

    L4OTHERCited in: History and Evolution of Treatment
  495. [495]

    Gencer B, Djousse L, Al-Ramady OT et al.. “Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.” Circulation (2021). PMID: 34612056 ↗

    L1SR_MA_RCTCited in: Complications, Prognosis and Natural History
  496. [496]

    Butt JH, Jhund PS, Henderson AD et al.. “Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.” European journal of heart failure (2025). PMID: 40222820 ↗

    L1RCTCited in: Complications
  497. [497]

    Triposkiadis F, Pieske B, Butler J et al.. “Global left atrial failure in heart failure.” European journal of heart failure (2016). PMID: 27813305 ↗

    L5REVIEW_NARRATIVECited in: Complications
  498. [498]

    Alzubi AS, Abdelaziz AM, Chukr M et al.. “Meta-analysis of the safety of outpatient Sotalol initiation in clinical practice.” Indian pacing and electrophysiology journal (2026). PMID: 42372971 ↗

    L1SR_OBSCited in: Complications
  499. [499]

    Akoum A, Hakim M, Kwayess R et al.. “Subclinical primary aldosteronism and major adverse cardiovascular events: evidence for a continuum of renin-independent aldosterone excess and a proposal for early detection.” Frontiers in cardiovascular medicine (2026). PMID: 42415983 ↗

    L5REVIEW_NARRATIVECited in: Complications
  500. [500]

    Purkarthofer D, Bachner V, Labenbacher S et al.. “Device damage and malfunction during dual defibrillation or dual electrical cardioversion: a scoping review.” Resuscitation (2026). PMID: 42385983 ↗

    L5REVIEW_NARRATIVECited in: Complications
  501. [501]

    McIntyre WF, Benz AP, Becher N et al.. “Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.” Circulation (2023). PMID: 37952187 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  502. [502]

    Kuno T, Takagi H, Ando T et al.. “Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis.” Journal of the American College of Cardiology (2020). PMID: 31976865 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  503. [503]

    Milling TJ, Middeldorp S, Xu L et al.. “Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.” Circulation (2023). PMID: 36802876 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis and Natural History
  504. [504]

    Connolly SJ, Ezekowitz MD, Yusuf S et al.. “Dabigatran versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2009). PMID: 19717844 ↗

    L1RCTCited in: Prognosis and Natural History
  505. [505]

    Rienstra M, Damman K, Mulder BA et al.. “Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.” JACC. Heart failure (2013). PMID: 24621795 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  506. [506]

    Savarese G, Giugliano RP, Rosano GM et al.. “Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.” JACC. Heart failure (2016). PMID: 27614940 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  507. [507]

    Mebazaa A, Nieminen MS, Packer M et al.. “Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.” JAMA (2007). PMID: 17473298 ↗

    L1RCTCited in: Prognosis and Natural History
  508. [508]

    Zeldin L, Eichler JBS, Teruya SL et al.. “Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy.” European journal of heart failure (2024). PMID: 39638976 ↗

    L3OTHERCited in: Prognosis and Natural History
  509. [509]

    Perdeck J, Knops RE, de Groot JR et al.. “Predicted adherence and ischaemic stroke risk in atrial fibrillation patients initiating oral anticoagulation: A cohort study of the medication adherence score.” International journal of cardiology (2026). PMID: 42401295 ↗

    L3COHORTCited in: Prognosis and Natural History
  510. [510]

    Ommen SR, Mital S, Burke MA et al.. “2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2020). PMID: 33215938 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  511. [511]

    Ommen SR, Ho CY, Asif IM et al.. “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2024). PMID: 38727647 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  512. [512]

    Arnett DK, Blumenthal RS, Albert MA et al.. “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2019). PMID: 30894319 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  513. [513]

    Heidenreich PA, Bozkurt B, Aguilar D et al.. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2022). PMID: 35379504 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  514. [514]

    Miyauchi K, Iwata H, Nishizaki Y et al.. “Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).” Circulation (2024). PMID: 38873793 ↗

    L1RCTCited in: Special Populations and Prevention
  515. [515]

    Kapadia SR, Krishnaswamy A, Whisenant B et al.. “Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation.” Circulation (2023). PMID: 37874908 ↗

    L1RCTCited in: Special Populations and Prevention
  516. [516]

    Nicolau AM, Giugliano RP, Zimerman A et al.. “Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy.” Journal of the American College of Cardiology (2025). PMID: 40769671 ↗

    L1RCTCited in: Special Populations and Prevention
  517. [517]

    Huang H, Liu Y, Shuai W et al.. “Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial.” European heart journal (2024). PMID: 39178138 ↗

    L1RCTCited in: Special Populations and Prevention
  518. [518]

    Okumura K, Akao M, Yoshida T et al.. “Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 32865374 ↗

    L1RCTCited in: Special Populations and Prevention
  519. [519]

    Mas JL, Derumeaux G, Guillon B et al.. “Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.” The New England journal of medicine (2017). PMID: 28902593 ↗

    L1RCTCited in: Special Populations and Prevention
  520. [520]

    Søndergaard L, Kasner SE, Rhodes JF et al.. “Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.” The New England journal of medicine (2017). PMID: 28902580 ↗

    L1RCTCited in: Special Populations and Prevention
  521. [521]

    Zheng Z, Jayaram R, Jiang L et al.. “Perioperative Rosuvastatin in Cardiac Surgery.” The New England journal of medicine (2016). PMID: 27144849 ↗

    L1RCTCited in: Special Populations and Prevention
  522. [522]

    Wazni OM, Dandamudi G, Sood N et al.. “Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 33197158 ↗

    L1RCTCited in: Special Populations and Prevention
  523. [523]

    Yusuf S, Healey JS, Pogue J et al.. “Irbesartan in patients with atrial fibrillation.” The New England journal of medicine (2011). PMID: 21388310 ↗

    L1RCTCited in: Special Populations and Prevention
  524. [524]

    Heneghan C, Ward A, Perera R et al.. “Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data.” Lancet (London, England) (2011). PMID: 22137798 ↗

    L1SR_OBSCited in: Special Populations and Prevention
  525. [525]

    d'Arcy JL, Coffey S, Loudon MA et al.. “Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study.” European heart journal (2016). PMID: 27354049 ↗

    L2COHORTCited in: Special Populations and Prevention
  526. [526]

    Kumar RK, Antunes MJ, Beaton A et al.. “Contemporary Diagnosis and Management of Rheumatic Heart Disease: Implications for Closing the Gap: A Scientific Statement From the American Heart Association.” Circulation (2020). PMID: 33073615 ↗

    L1REVIEW_NARRATIVECited in: Special Populations and Prevention
  527. [527]

    Siscovick DS, Barringer TA, Fretts AM et al.. “Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.” Circulation (2017). PMID: 28289069 ↗

    L1REVIEW_NARRATIVECited in: Special Populations and Prevention
  528. [528]

    Stewart S, Ball J, Horowitz JD et al.. “Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial.” Lancet (London, England) (2014). PMID: 25467562 ↗

    L1RCTCited in: Special Populations and Prevention
  529. [529]

    Bousser MG, Bouthier J, Büller HR et al.. “Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.” Lancet (London, England) (2008). PMID: 18294998 ↗

    L1RCTCited in: Special Populations and Prevention
  530. [530]

    Macle L, Khairy P, Weerasooriya R et al.. “Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial.” Lancet (London, England) (2015). PMID: 26211828 ↗

    L1RCTCited in: Special Populations and Prevention
  531. [531]

    Mullens W, Dauw J, Martens P et al.. “Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics.” European journal of heart failure (2022). PMID: 35733283 ↗

    L1RCTCited in: Special Populations and Prevention
  532. [532]

    Cheng L, Hammersley D, Ragavan A et al.. “Long-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission.” European journal of heart failure (2024). PMID: 39349993 ↗

    L2RCTCited in: Special Populations and Prevention
  533. [533]

    Mulder BA, van Veldhuisen DJ, Crijns HJ et al.. “Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS.” European journal of heart failure (2012). PMID: 22764183 ↗

    L1RCTCited in: Special Populations and Prevention
  534. [534]

    Kirchhof P, Calkins H. “Catheter ablation in patients with persistent atrial fibrillation.” European heart journal (2016). PMID: 27389907 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  535. [535]

    Ajjan RA, Kietsiriroje N, Badimon L et al.. “Antithrombotic therapy in diabetes: which, when, and for how long?” European heart journal (2021). PMID: 33764414 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  536. [536]

    van den Berg MP, Mulder BA, Klaassen SHC et al.. “Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.” European heart journal (2019). PMID: 30753432 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  537. [537]

    Patel SM, Giugliano RP, Morrow DA et al.. “Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40888686 ↗

    L1RCTCited in: Special Populations and Prevention
  538. [538]

    Hijazi Z, Hohnloser SH, Andersson U et al.. “Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.” JAMA cardiology (2016). PMID: 27438322 ↗

    L1RCTCited in: Special Populations and Prevention
  539. [539]

    Sliwa K, Azibani F, Johnson MR et al.. “Effectiveness of Implanted Cardiac Rhythm Recorders With Electrocardiographic Monitoring for Detecting Arrhythmias in Pregnant Women With Symptomatic Arrhythmia and/or Structural Heart Disease: A Randomized Clinical Trial.” JAMA cardiology (2020). PMID: 32074256 ↗

    L1RCTCited in: Special Populations and Prevention
  540. [540]

    Steinberg JS, Shabanov V, Ponomarev D et al.. “Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.” JAMA (2020). PMID: 31961420 ↗

    L1RCTCited in: Special Populations and Prevention
  541. [541]

    Ahmed S, Rienstra M, Crijns HJ et al.. “Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial.” JAMA (2008). PMID: 18854540 ↗

    L1RCTCited in: Special Populations and Prevention
  542. [542]

    Lam CS, Carson PE, Anand IS et al.. “Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.” Circulation. Heart failure (2012). PMID: 22887722 ↗

    L1RCTCited in: Special Populations and Prevention
  543. [543]

    Gomez KA, Tromp J, Figarska SM et al.. “Distinct Comorbidity Clusters in Patients With Acute Heart Failure: Data From RELAX-AHF-2.” JACC. Heart failure (2024). PMID: 38970586 ↗

    L1RCTCited in: Special Populations and Prevention
  544. [544]

    Steinberg BA, Al-Khatib SM, Edwards R et al.. “Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.” JACC. Heart failure (2014). PMID: 25306452 ↗

    L1SR_OBSCited in: Special Populations and Prevention
  545. [545]

    Mehta R, Cai X, Lee J et al.. “Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.” JAMA cardiology (2016). PMID: 27434583 ↗

    L2COHORTCited in: Special Populations and Prevention
  546. [546]

    Cheng X, Song C, Ouyang F et al.. “Systolic blood pressure variability: risk of cardiovascular events, chronic kidney disease, dementia, and death.” European heart journal (2025). PMID: 40249367 ↗

    L2OTHERCited in: Special Populations and Prevention
  547. [547]

    Taageby Nielsen S, Luo J, Tybjærg-Hansen A et al.. “Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.” European heart journal (2025). PMID: 40900121 ↗

    L2OTHERCited in: Special Populations and Prevention
  548. [548]

    González-López E, Gallego-Delgado M, Guzzo-Merello G et al.. “Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.” European heart journal (2015). PMID: 26224076 ↗

    L2OTHERCited in: Special Populations and Prevention
  549. [549]

    Wu X, Meng J, Yang Y et al.. “Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis.” Renal failure (2026). PMID: 42128628 ↗

    L1SR_OBSCited in: Special Populations and Prevention
  550. [550]

    Eikelboom JW, Quinlan DJ, Hirsh J et al.. “Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.” JAMA cardiology (2017). PMID: 28355459 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  551. [551]

    Berbert GH, Andalaft RB, Valdigem BP et al.. “Cilostazol for heart rate increase in atrial fibrillation with slow ventricular response: an exploratory randomized controlled trial.” European heart journal open (2026). PMID: 42146871 ↗

    L1RCTCited in: Special Populations and Prevention
  552. [552]

    Al-Shammari AS, Amin AM, Awashra A et al.. “Clinical outcomes after catheter ablation for atrial fibrillation in elderly patients: a meta-analysis with time-to-event data reconstruction.” Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2026). PMID: 42340581 ↗

    L1SR_OBSCited in: Special Populations and Prevention
  553. [553]

    Li L, Shah A, Ko YA et al.. “Sedentary behavior with atrial fibrillation-related biomarkers in overweight or obese adults.” BMC cardiovascular disorders (2026). PMID: 42121060 ↗

    L2RCTCited in: Special Populations and Prevention
  554. [554]

    Porcari A, Razvi Y, Masi A et al.. “Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.” European journal of heart failure (2023). PMID: 36644836 ↗

    L4OTHERCited in: Special Populations and Prevention
  555. [555]

    Dhont S, Moura-Ferreira S, Bekhuis Y et al.. “Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea.” European journal of heart failure (2026). PMID: 41802264 ↗

    L2OTHERCited in: Special Populations and Prevention
  556. [556]

    Spagnolin M, Fazzini L, Giaccherini C et al.. “Outcome trajectories in hospitalized heart failure with preserved ejection fraction: a machine learning cluster analysis.” European journal of heart failure (2026). PMID: 41740597 ↗

    L2OTHERCited in: Special Populations and Prevention
  557. [557]

    Siddiqi TJ, Anker SD, Filippatos G et al.. “Health status across major subgroups of patients with heart failure and preserved ejection fraction.” European journal of heart failure (2023). PMID: 36974746 ↗

    L2OTHERCited in: Special Populations and Prevention
  558. [558]

    Yang H, Negishi K, Wang Y et al.. “Echocardiographic screening for non-ischaemic stage B heart failure in the community.” European journal of heart failure (2016). PMID: 27813300 ↗

    L2OTHERCited in: Special Populations and Prevention
  559. [559]

    Elkind MSV. “Prevention of Stroke.” Continuum (Minneapolis, Minn.) (2026). PMID: 42233818 ↗

    L5CASE_REPORTCited in: Special Populations and Prevention
  560. [560]

    Ballin M, Carlsson AC, Wändell P et al.. “Adolescent Cardiorespiratory Fitness and the Trade-Off Between Atrial Fibrillation Risk and Cardiovascular Benefits: A Nationwide Sibling-Controlled Cohort Study.” Circulation (2026). PMID: 42165142 ↗

    L2COHORTCited in: Special Populations and Prevention
  561. [561]

    Crump C, Wei J, Sundquist J et al.. “Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation.” JAMA cardiology (2025). PMID: 41123920 ↗

    L2OTHERCited in: Special Populations and Prevention
  562. [562]

    Mo X, Janszky I, Wang H et al.. “Maternal Diabetes and Risk of Early-Onset Cardiovascular Diseases in Offspring.” JAMA cardiology (2026). PMID: 42126857 ↗

    L2OTHERCited in: Special Populations and Prevention
  563. [563]

    Carrero JJ, Evans M, Szummer K et al.. “Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.” JAMA (2014). PMID: 24595776 ↗

    L2OTHERCited in: Special Populations and Prevention
  564. [564]

    Barasch E, Gottdiener JS, Aurigemma G et al.. “Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study.” Circulation. Heart failure (2009). PMID: 19808353 ↗

    L3OTHERCited in: Special Populations and Prevention
  565. [565]

    Januzzi JL, Packer M, Claggett B et al.. “IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.” Circulation. Heart failure (2018). PMID: 30354399 ↗

    L2OTHERCited in: Special Populations and Prevention
  566. [566]

    Lanfear DE, Luzum JA, She R et al.. “Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.” Circulation. Heart failure (2020). PMID: 33012170 ↗

    L2OTHERCited in: Special Populations and Prevention
  567. [567]

    Goyal A, Norton CR, Thomas TN et al.. “Predictors of incident heart failure in a large insured population: a one million person-year follow-up study.” Circulation. Heart failure (2010). PMID: 20798277 ↗

    L2OTHERCited in: Special Populations and Prevention
  568. [568]

    Murad K, Goff DC, Morgan TM et al.. “Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study.” JACC. Heart failure (2015). PMID: 26160370 ↗

    L2OTHERCited in: Special Populations and Prevention
  569. [569]

    Patel N, Ju C, Macon C et al.. “Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry.” JACC. Heart failure (2016). PMID: 26874392 ↗

    L2OTHERCited in: Special Populations and Prevention
  570. [570]

    Lu J, Sun S, Shang X et al.. “Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.” International journal of medical sciences (2026). PMID: 42328113 ↗

    L2SR_OBSCited in: Special Populations and Prevention
  571. [571]

    Littman E, Bukhari S, Watts H et al.. “Beyond the Coronaries: Utility of Extra-Coronary Calcification for Cardiovascular Risk Assessment in Women.” Current atherosclerosis reports (2026). PMID: 42189365 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  572. [572]

    Johner N, Gencer B. “Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation.” European journal of clinical investigation (2026). PMID: 42148709 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  573. [573]

    Laterra G, Scalia L, Strazzieri O et al.. “Left Atrial Appendage Occlusion in the Era of Minimalist Approaches: Anesthesia and Imaging Considerations.” Journal of clinical medicine (2026). PMID: 42123128 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  574. [574]

    Bu F, Xu B, Han Y et al.. “Development of risk prediction model for new-onset atrial fibrillation in elderly patients undergoing video-assisted thoracoscopic surgery: a retrospective cohort study.” Journal of thoracic disease (2026). PMID: 42182761 ↗

    L3COHORTCited in: Special Populations and Prevention

Revision History

All updates applied to this page

Loading revisions…